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Organophosphates (OPs) are used in agriculture via pesticides, and warfare and
terrorism via nerve agents. OPs can inhibit acetylcholinesterase (AChE) activity in the
nervous system, leading to the buildup of acetylcholine (ACh), and overstimulation of the
nervous system and eventual asphyxiation and death. The development of novel bloodbrain barrier (BBB) penetrating pyridinium oxime reactivators have previously
demonstrated efficacy towards treatment of OP poisoning after exposure of rats to a sarin
or a VX surrogate, nitrophenyl isopropyl methylphosphonate (NIMP) and nitrophenyl
ethyl methylphosphonate (NEMP), respectively. An effective oxime antidote capable of
penetrating the BBB and restoring nervous system activity after exposure to a cyclosarin
surrogate, nitrophenyl cyclohexyl methylphosphonate (NCMP), has yet to be determined.
In Chapter 2, in vitro testing of the efficacy of 17 total novel oxime candidates to utilize
against NCMP was conducted with a modified Ellman’s AChE assay. Pools of naïve
adult male rat brains were utilized as the AChE source. The first variable investigated
was the measurement of AChE activity after inhibition with NCMP and subsequent
reactivation with one of the oximes. The second variable investigated restoration of

AChE activity after simultaneous oxime and NCMP incubation. The final variable
investigated the restoration of AChE activity after simultaneous 2-PAM, oxime and
NCMP incubation. A thorough kinetic analysis of our best oximes has yet to be
accomplished. In Chapter 3, the best oxime antidotes for NEMP and NIMP were used
for kinetic analysis with a modified 96-well plate Ellman’s AChE assay. Protein
concentrations were analyzed with a modified Lowry protein tube assay to ensure
consistent analytical concentrations. The sources of AChE included pooled rat brain and
skeletal muscle, and rat and human erythrocytes and plasma. Butyrylcholinesterase
(BChE) activity was also measured in the rat and human plasma samples. The results of
these studies strengthen the argument that our oxime antidotes can be used as potential
therapeutic drugs for OP poisoning. The kinetic data provided critical information to
help propose, for Chapter 4, a dynamic pharmacokinetic based model to predict human
AChE or BChE activity after exposure to nerve agent surrogates (NEMP and NIMP) and
the oximes (44.08 and 44.25).
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CHAPTER I
INTRODUCTION
Historical Background of Organophosphates
Organophosphates (OPs) were first discovered in the 19th century by Jean Louis
Lassaigne and Philippe de Clermont. Lassaigne synthesized the compound by reacting
alcohol with phosphoric acid and Clermont presented tetraethyl pyrophosphate at a
French Academy of Science meeting (Fest and Schmidt 1982). The effect on the
cholinergic system was described in 1932 by German chemist Willy Lange and Gerduh
von Krueger. The scientists observed that OP exposure caused eye sight problems via
pupil dilation with the resulting increased light sensitivity. Most importantly they
observed that OP exposure induced respiratory distress and shortness of breath. Around
the late 1930s, Gerhard Schrader began to develop the OPs for insecticidal use. Under
German law all research with the potential for warfare applications were required to be
reported to the Nazi government. Dr. Schrader was eventually ordered to develop OPs
into weapons of war (Tucker 2007). The compounds were classified as
organophosphates since they contain a phosphorus element in their structure.
The G-series nerve agents were the first developed and the most widely used
historically. They include GA (tabun) created in 1936, GB (sarin) created in 1938, GD
(soman) created in 1944, and GF (cyclosarin) created in 1949. The V agents were
developed around 1954 by the British. They include VE, VG, VM, and VX. The
1

Russians developed VR in the 1960s. The biggest strategic difference between the G and
V-series agents is persistence. G agents are considered non-persistent, while V agents are
very persistent and do not degrade or wash away easily. GB and VX are the only agents
fielded by the US military as munitions in rockets, aerial bombs, and artillery shells
(United States. Department of the Army, Institute of Land Warfare et al. 1967).
Currently nerve agents have been classified as chemical weapons and are considered by
the United Nations (UN) as weapons of mass destruction. The terms of this ruling are
described in UN Resolution 687 which was passed in 1991. The Chemical Weapons
Convention of 1993 outlaws the production of and stockpiling of any chemical weapons.
In addition, the use of chemical weapons during warfare is not permitted by treaties
signed during the Hague Conventions of 1899 and 1907 and the 1925 Geneva Protocol
(Tuorinsky, United States. Dept. of the Army. Office of the Surgeon General. et al.
2008).
After WWII, American companies used Dr. Schrader’s research to create several
OP pesticides, some of which are still in use today like malathion, parathion, and many
others. OPs became increasingly popular with the banning of organochlorines in the
1970s. As an insecticide, OPs are used extensively throughout the world. Most
poisonings occur as a result of work related exposures and lapses in the use of personal
protective equipment and contamination of food sources (van Heel and Hachimi-Idrissi
2011, Vučinić, Antonijević et al. 2014, Coskun, Gundogan et al. 2015, Muñoz-Quezada,
Lucero et al. 2016). In some cases, particularly in rural areas of undeveloped and
developed countries, OPs are used in suicides (Eddleston 2000, Buckley, Karalliedde et
al. 2004, Pandit, Seshadri et al. 2011).
2

Besides OPs being used as pesticides, there is a concern that OP nerve agents may
be used as weapons during warfare and also as a means of terrorist attacks throughout the
world. Prime examples of nerve agent being used in war include the Iran-Iraq War, and
recently the Syrian civil war (Tuorinsky, United States. Dept. of the Army. Office of the
Surgeon General. et al. 2008). During the end of the Iran-Iraq War in 1988, the Iraqi
forces unleashed a chemical attack on Iranian forces in the city of Halabjah, leaving over
4000 dead and 6000 injured combatants and civilians (Rose and Baravi 1988). More
recently in 2013, a nerve agent attack was conducted in Damascus with the Syrian Civil
War. Death estimates ranged from 1400 to 1500 with 426 of those children and around
3600 more severely affected (Dolgin 2013, Pita and Domingo 2014, Rosman, Eisenkraft
et al. 2014).
Even more dangerous are terrorists who are using unconventional methods, such
as nerve agents to strengthen their position and/or force their beliefs on the whole of
society. One example is the Tokyo subway attacks in 1995 (Tuorinsky, United States.
Dept. of the Army. Office of the Surgeon General. et al. 2008). The Aum Shinrikyo
religious sect launched a sarin gas attack in the Tokyo subways during rush hour. The
result was 12 killed, over 1000 temporarily injured, and 50 permanently injured
neurologically. The rising concerns of homegrown terrorist attacks brought on by the
surge in ISIS propaganda has also increased the necessity for improved prevention of
nerve agent attacks and treatment of those exposed. It is imperative that better nerve
agent antidotes be developed to counteract and/or deter possible terrorist attacks and also
decrease detrimental effects of pesticide poisonings throughout the world.
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Organophosphate Mechanism of Action
The nervous system helps coordinate a majority of the voluntary and involuntary
functions and assists in the coordination between various parts of the body (Tortura 2011,
Kandel 2013). It consists of the brain, spinal cord, and peripheral nerves (Tortura 2011,
Kandel 2013). It accomplishes communication primarily through the formation of nerve
impulses or action potentials (Tortura 2011, Kandel 2013). As a whole, it plays a vital
role in our perceptions, behaviors, memories, movements, and control of homeostasis
throughout the body (Kandel 2013). Within the system there are various elements that
play a role in conducting the complex network of communication. Some of those
elements include concentration gradients of potassium, sodium, and calcium. Along with
their corresponding membrane ion channels, they work together to help with the
conduction of electrical signals. Other components of the nervous system provide vital
cellular support like oligodendrocytes, astrocytes, and Schwann cells that assist with
overall maintenance and up keep of the system streamlining the communication (Tortura
2011, Kandel 2013). One of the most important components of the nervous system are
the neurotransmitters which provide communication between separate nerve cells via the
synaptic cleft that separates them (Tortura 2011, Kandel 2013).
In the normal nerve, a presynaptic cell and a postsynaptic cell provide an
important junction in the nerve cell communication and provide the main means utilized
by nerve agents for their mechanism of toxicity. At the transition point between the two
neurons, the electrical signal turns into a chemical signal via the acetylcholine (ACh)
ligand. The ligand communicates to the next cell by binding a receptor (nicotinic or
muscarinic) on the postsynaptic cell. When an action is no longer needed the ligand is
4

cleared by acetylcholinesterase (AChE; EC 3.1.1.7) which is bound to the postsynaptic
cell membranes and the nerve cell stimulation is stopped. In the nicotinic system, the
ACh binds to nicotinic cholinergic receptors that open to allow flux of ions and initiates
the next nerve impulse (Kabbani, Nordman et al. 2013). In mammals, the nicotinic
receptors mainly control voluntary muscle movements. In the muscarinic system, the
ACh binds to receptors that affect G-protein signaling, which signals either the cAMP or
phosphatidylinositol (PI) pathways (Strader, Fong et al. 1994). The muscarinic receptors
mainly affect the autonomic nervous system and control actions like salivation,
lacrimation, digestion, and sexual arousal. At a molecular level, cAMP and PI can play a
role in intracellular signal transduction, lipid signaling, cell signaling, membrane
trafficking, and activation of protein kinases (Rosenbaum, Rasmussen et al. 2009). OPs
block AChE from interacting with the ACh ligand and prevent its subsequent metabolism
into acetate and choline. The latter of which is recycled by the presynaptic cell to create
more ACh. The loss of AChE activity results in ACh buildup in the synapse and causes
continued stimulation of the affected receptors. Generally, the concentration and type of
OP exposure determines the signs and symptoms of those exposed and can range from
irritation to death (Tuorinsky, United States. Dept. of the Army. Office of the Surgeon
General. et al. 2008).
Biological Importance of Acetylcholine and Butyrylcholinesterase
The most important and best-studied neurotransmitter when discussing nerve
agents is acetylcholine (ACh). ACh is utilized in neuromuscular junctions of the
autonomic and the somatic nervous systems and also at various sites within the central
nervous system (Purves D 2001). Within the nerve cell, ACh is derived from the
5

conversion of glucose into pyruvate (Taylor 1999). Glycolysis is the process that
converts glucose into pyruvate. Once pyruvate is formed, then it is converted to acetyl
coenzyme A (acetyl CoA). In nerve cells, choline acetyl transferase interacts with acetyl
CoA and choline to form ACh. The ACh is then placed in vesicles for release into the
synapse when electrically stimulated by a nerve impulse. Once released into the synaptic
cleft, the ACh in the cleft binds to ACh receptors on the adjacent nerve or effector cell as
mentioned previously. The bound ACh stimulates another electrical signal, and then is
released from the ACh receptor. The stimulation continues as long as the ACh remains in
the synapse or neuromuscular junction. To clear the synapse of ACh,
acetylcholinesterase (AChE) within the synapse or neuromuscular junction cleaves the
ACh into acetate and choline. Choline is actively taken back into the presynaptic nerve
terminal via a Na+/choline transporter for reuse (Purves D 2001, Amenta and Tayebati
2008).
Butyrylcholinesterase (BChE; EC 3.1.1.8) is an enzyme primarily suspended in
the plasma (Kolarich, Weber et al. 2008). A natural ligand for the enzyme would be
butyrylcholine (BCh) but it does not occur in the body naturally. It can be used to help
distinguish between AChE and BChE activity. BChE is also known as
pseudocholinesterase or plasma cholinesterase and interacts with many different choline
esters making it a non-specific cholinesterase. This non-specific nature allows BChE to
play a significant role in the metabolism of procaine, heroin, cocaine, mivacurium,
succinylcholine, and a variety of similar compounds (Cook, Stiller et al. 1989, Carmona,
Jufer et al. 2000, Hou, Zhan et al. 2014). Though BChE is primarily located in the
plasma, recent studies have found BChE in the brain and cerebrospinal fluid and have
6

demonstrated possible reactivity with ACh (Nordberg, Ballard et al. 2013). In the realm
of chemical warfare, BChE has been sought out as a possible countermeasure against
nerve agents by acting as a scavenger of OPs (Masson and Lockridge 2010, Nachon,
Brazzolotto et al. 2013). It can interact with the nerve agent while it is in the bloodstream
decreasing nervous system interaction (Raveh, Grunwald et al. 1993, Lenz, Yeung et al.
2007).
OP Poisoning Signs and Symptoms and Diagnostic Testing
According to the Centers for Disease Control and Prevention website page on
emergency preparedness there are a variety of signs and symptoms for OP poisoning and
a variety of diagnostic testing options are available (Peter, Sudarsan et al. 2014). Central
nervous system toxicity causes miosis, headache, restlessness, convulsions, loss of
consciousness, and coma. Respiratory system toxicity can lead to rhinorrhea,
bronchorrhea, wheezing, dyspnea, chest tightness, hyperpnea, and bradypnea.
Cardiovascular system toxicity can result in tachycardia, bradycardia, other arrhythmias,
hypertension and hypotension arrhythmias. Gastrointestinal system toxicity results in
abdominal pain, nausea, vomiting, and diarrhea. Toxicity can also lead to urinary
incontinence. Musculoskeletal system toxicity causes weakness and fasciculation. Skin
and mucous membrane toxicity leads to profuse sweating, lacrimation, and conjunctival
hyperemia (Tuorinsky, United States. Dept. of the Army. Office of the Surgeon General.
et al. 2008). Once OP exposure is suspected, blood testing for cholinesterase activity can
be performed by assessing plasma BChE or erythrocyte AChE activity (Bajgar 2004,
Worek, Koller et al. 2005). Erythrocyte AChE better reflects CNS AChE activity than
plasma does and is also more specific than plasma assays. On the other hand, plasma
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BChE is easier to assay than erythrocyte AChE and is more commonly available and
widely used in clinical chemistry analyzers (van Heel and Hachimi-Idrissi 2011, Worek,
Schilha et al. 2016). Decreases in BChE or AChE activity only suggest poisoning, but
cannot rule out specifically the cause, but patient history can further validate the source
of poisoning (Bajgar 2004). Once OP poisoning is identified, immediate treatment
involves enzyme reactivation via oximes and blocking nerve cell receptors with atropine.
Nerve Agent Antidotes
The general treatment involves the administration of atropine to block the effects
of the nerve agent and 2-pyridine aldoxime methyl chloride (2-PAM Cl, also called 2pralidoxime chloride; pyridine-2-aldoxime methyl chloride; 2-formyl-1methylpyridinium chloride) to reactivate inhibited AChE (Kassa 2002, Smythies and
Golomb 2004). The 2-PAM oxime reactivates AChE by removing the phosphyl moiety.
In general, most reactivators remove inhibitors via their attached nitrogen-associated
hydroxyl group. The hydroxyl loses its hydrogen and becomes bound to the phosphorous
group of the inhibitor. The phosphorous group releases its bond with AChE. AChE is
thereby reactivated and once again is able to break down ACh. Atropine is administered
to temporarily block the muscarinic ACh receptors, preventing further stimulation by
ACh that is building up in the synapse. The temporary blocking of the ACh receptors
prevents continued stimulation by ACh until the ACh can be cleared from the synapse.
2-PAM is only effective against an OP that has not released any of its side groups
while attached to AChE, in other words it has not “aged”. The OP side groups help to
pull electrons away from the OP phosphorous core maintaining a neutral charge easily
broken by 2-PAM. By losing a side group while covalently attached to an OP, the AChE
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is “aged” and is resistant to reactivation by hydrolysis or an oxime antidote because of
the phosphylated enzyme (Tuorinsky, United States. Dept. of the Army. Office of the
Surgeon General. et al. 2008). The reaction for aging or dealkylation is centered on the
interaction of amino acids located in the active site gorge with the phosphyl moiety of the
OP and the splitting of the complex that forms the alcohol and nonreactivatable AChE
(Bajgar 2004). Normally AChE bound by an OP can be naturally reactivated by
hydrolysis within the normal operating nervous system, until aging takes place. The only
way to combat inhibited AChE that has aged is to generate a new AChE molecule. Other
antidotes similar to 2-PAM include asoxime (HI-6) and obidoxime chloride (Yang 2003).
2-PAM is the only antidote approved by the Food and Drug Administration (FDA) for
use in the United States.
Another means to combat nerve agent poisoning is to provide prophylactic drugs
like pyridostigmine bromide (PB) which is a carbamate AChE inhibitor (Tuorinsky,
United States. Dept. of the Army. Office of the Surgeon General. et al. 2008). PB has
been tested in primate models demonstrating 40 to 50% protection over a period of 1 to 6
hours and several other animal models (Shiloff and Clement 1986, von Bredow, Adams
et al. 1991, Maxwell, Brecht et al. 1993). Prophylactic drugs like PB temporarily bind
AChE and prevent OP nerve agents from binding. The carbamylated enzyme can
regenerate naturally via hydrolysis much more quickly than the phosphylated AChE can
regenerate spontaneously. Once AChE function is restored then ACh is metabolized and
returned to normal levels.
Diazepam (valium), a benzodiazepine, has been used to prevent convulsions and
enhance nerve agent antidotes during moderate to severe exposures (Marrs 2003). The
9

action of diazepam is mediated through gamma-aminobutyric acid (GABA) receptors
which activates ligand-gated chloride ion channels to inhibit neurotransmission with the
influx of chloride ions to dissipate the electrical signal. This reduces convulsions and
prevents nervous system damage from overstimulation.
Improving Nerve Agent Antidote by Crossing Blood Brain Barrier
In the late 19th century scientists noticed that certain dyes administered
peripherally did not stain tissue in the CNS (Davson and Segal 1996, Banks 2008). Many
explored theories focused on differences in CNS tissue affinity to vasculature of the
brain, but it was not until the 1960s and 1970s that scientists began to explore the ultrastructures of the body (Davson and Segal 1996). It was then that Karnovsky, Reese, and
Brightman found that brain capillary beds had tight junctions, pinocytosis was decreased
significantly, and fenestrations were absent (Brightman 1977). These structural
modifications prevent plasma ultra filtrate from forming and hence plasma proteins like
albumin could not cross the blood brain barrier (BBB). Since the dyes adhere to albumin
they were unable to stain CNS tissue. Transport systems were later identified that
allowed a variety of substances to enter the CNS circulation like glucose, amino acids,
vitamins, minerals, fatty acids, and electrolytes. Many researchers have exploited all
these avenues of transport, but the primary mechanism utilized for drug delivery is
transmembrane diffusion and saturable transport (Begley 2004). The major hindrance to
diffusion is the polarity of a molecule where highly polar molecules are prevented from
crossing the BBB. Lipophilic molecules can easily diffuse through the BBB and
passively enter the CNS (Levin 1980). This is not the case for some lipophilic molecules
which can be actively transported out of the CNS in some situations. To cross the BBB,
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Dr. Howard Chambers synthesized phenoxyalkyl pyridinium oximes with a variety of Rgroup attachments that provide a more lipophilic structure. This lipophilicity may allow
for improved BBB crossing and reactivation of brain AChE for some of the developed
chemicals, but the exact mechanism has yet to be determined (Chambers, Chambers et al.
2013). Dr. Janice Chambers and her laboratory have successfully tested a variety of these
novel oximes in in vivo rat models and demonstrated a few can cross the BBB and restore
OP inhibited AChE. This is an improvement from the currently used oxime antidote,
pralidoxime chloride (2-PAM), which only reverses inhibited AChE in the peripheral
nervous system (Kassa 2002, Smythies and Golomb 2004). The polarity of 2-PAM
prevents it from crossing the BBB (Worek, Eyer et al. 2007, Joosen, van der Schans et al.
2011). Bis-quaternary oxime compounds like HI-6, MMB-4, and obidoxime improve
their reactivation capabilities with a second cation, but also have problems crossing the
BBB because of their positive charge (Kalisiak, Ralph et al. 2011). The nomenclature for
Dr. Chambers’ novel oximes is defined by the first digit which is the position of the
oxime in relationship to the quaternary nitrogen in the pyridinium ring, second digit is the
n describing number of methylene’s in the methylene bridge, and the final double digit is
the sequence of the compound within the series.
The recent development of novel nerve agent surrogates has allowed for easier
testing of nerve agents without the usual scrutiny and security required for military grade
nerve agent usage (Meek, Chambers et al. 2012). The developed nerve agent surrogates
provide the same inhibitor-AChE complex as seen with the normal nerve agents. The
difference is in the leaving group, which decreases the potency compared to the actual
nerve agent. Utilizing these nerve agent surrogates, the novel oxime antidotes were
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tested and demonstrated their potential for BBB crossing in rats (Chambers, Chambers et
al. 2013). Nerve agents that reach the brain can have permanent detrimental effects to
higher level motor and cognitive function. OP compounds are lipophilic and are able to
cross the BBB to inhibit AChE. Besides the novel oximes currently being developed,
there are a few other antidotes that explore other mechanisms to cross the BBB. Nonpolar neutral compounds in development have demonstrated effectiveness in crossing the
BBB in mice (Radic, Sit et al. 2012). These neutral hydroxyimino-acetamido alkylamine
compounds have been successfully tested in vivo with mice models and refined in vitro
using purified commercial human AChE (Sit, Radic et al. 2011, Radic, Sit et al. 2012,
Radić, Sit et al. 2013). The compounds are devoid of charge, but the oxime group and
amine group causes a coexistence of a charge and uncharged states at physiological pH.
The charged state assists with AChE reactivation and the uncharged state allows BBB
penetration. Another approach for BBB crossing uses amidine-oxime reactivators which
are also more lipophilic than 2-PAM and have resulted in 24 hour mice survival after
sarin exposure (Kalisiak, Ralph et al. 2011, Kalisiak, Ralph et al. 2012). The amidine
moiety provides a pseudo charge that allows efficient binding of OP-inhibited ChEs,
while the oxime group reactivates the phosphylated ChE. Researchers have also
developed novel sugar-oxime conjugates to reactivate inhibited CNS AChE by attaching
glucose to 2-PAM (Garcia, Campbell et al. 2010). The sugar oximes have the potential to
be transported across the BBB via glucose transporters and have demonstrated
effectiveness in peripheral AChE restoration. Prodrugs associated with 2-PAM have also
been considered, but synthesis is difficult and autoxidation is common (Shek, Higuchi et
al. 1976, Shek, Higuchi et al. 1976, Demar, Clarkson et al. 2010). Pro-2-PAM has
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demonstrated effectiveness in guinea pig models exposed to a sarin surrogate
diisopropyl-fluorophosphate (DFP) (Demar, Clarkson et al. 2010).
Choosing the Best Kinetic Model
Over 100 years ago Leonor Michaelis and Maud Menten published their work on
enzyme kinetics and their famous Michaelis-Menten equation. In their work, they
demonstrated that the rate of an enzyme-catalyzed reaction is proportional to the enzymesubstrate complex. The equation follows a mechanism in which substrate binds
reversibly to an enzyme to form an enzyme-substrate complex, which then reacts
irreversibly and generates a product and the free enzyme. In 2011, their work was
officially translated to English, reevaluated using computer programs, and published by
Kenneth Johnson and Roger Goody (Michaelis, Menten et al. 2011). Utilizing
modifications of the original equation, many nerve agent researchers use the equation to
demonstrate how effective their oximes, nerve agents, or nerve agent surrogates work
kinetically. This provides a basis from which researchers can compare and help
determine the effectiveness of their compounds.
The current research continues to utilize the kinetic concepts developed by
Michaelis -Menten to demonstrate the effectiveness of AChE and BChE inhibition by
new nerve agent surrogates and subsequent reactivation by novel oximes. The kinetic
data generated will provide additional support towards demonstrating the viability of the
compounds for nerve agent research and further antidote testing. Demonstrating kinetic
differences between rat and human AChE and BChE will provide a better knowledge
base for determining human modeling based on rat experimental data. Three of the most
utilized kinetic models derived from the Michaelis-Menten equation include a standard
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Briggs-Haldane plot, an Eadie-Hofstee plot, and a Lineweaver-Burk plot (Briggs and
Haldane 1925, Michaelis, Menten et al. 2011). These various plots were utilized to obtain
the best fit line equation with a coefficient of determination statistic, R2-value, greater
than 0.9. Choosing the best kinetic model plot requires continued monitoring of the data
as it is being generated and determining which of the three plots provides consistent best
fit lines. From this line equation the necessary rate constants were calculated for all the
data.
The Briggs-Haldane model plots the velocity versus the inhibitor concentration
(vo versus inhibitor concentration). The inhibitor concentration could also be replaced
with substrate concentration depending on what kinetic values are required. It provides
direct analysis of the data without any adjustment to the original data. In most cases
linear lines were demonstrated with R2-values greater then 0.9, occasionally the R2-value
was less than 0.9. The Eadie-Hofstee model plots the velocity versus the velocity divided
by the inhibitor concentration (vo versus vo/inhibitor concentration). In a few data sets,
dividing the velocity by the inhibition concentration on the x-axis provided improved
linearity. Yet in some cases the adjustment resulted in outliers and nonlinear equations
with a correlation coefficient far less than 0.9. The nonlinear data may be due to the
strong dependence of both the x and y-axis on the velocity data. Another concern is the
smaller concentrations and their increased weight when forming the linear equation and
best fit line. The weight of these smaller concentrations can sway the line dramatically
(Dowd and Riggs 1965). The various kinetic models have strengths and weaknesses
when investigating particular biological functions.
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The Lineweaver-Burk model plots the reciprocal of both velocity versus the
inhibitor concentration (1/vo versus 1/inhibitor concentration). All data sets demonstrated
the best linearity when using this model and the best correlation coefficient always
greater than 0.9. The major concern with this model was the smaller concentrations and
their increased weight when forming the linear equation and best fit line (Ritchie and
Prvan 1996, Ritchie and Prvan 1996). Utilizing this model, all the necessary kinetic
values were calculated utilizing kinetic calculations adopted from Worek et al. and Carr
et al. (Carr and Chambers 1996, Worek, Eyer et al. 1998, Worek, Reiter et al. 2002,
Worek, Thiermann et al. 2004). Ideally, studying enzymes in their natural environment is
considered to be the best approach, but experimentally it is hard to account for the variety
of conditions in such an environment. Consequently, extracted and purified enzymes
analyzed in vitro are the controlled experimental option. The current research maintains
some biological relevancy using plasma and purified membranes, but the downside is the
introduction of some unknown factors. Choosing the correct consistent model helps
negate some of these biological factors that can influence the kinetic values.
Kinetic Analysis and Bridging Rat and Human Models
Kinetic analysis of biological systems is important for understanding and
comparing systems (Resat, Petzold et al. 2009). To further understand the interactions
between the nerve agent surrogates and novel oxime antidotes it is imperative that a
kinetic analysis be performed. The knowledge of reaction rates is critical in providing a
means for comparative analysis between 2-PAM and any proposed replacements. 2PAM is currently the FDA approved antidote in the United States. Many researchers
have utilized kinetic analysis to quantify reactions occurring with various oximes and
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OPs. Researchers have also performed similar kinetic analyses to look at
acetylcholinesterase activity in various animal and human models (Worek, Reiter et al.
2002, Worek, Aurbek et al. 2007, Aurbek, Herkert et al. 2010, Herkert, Freude et al.
2012, Coban, Carr et al. 2016) Utilizing their research precedent, procedures for kinetic
analysis of our nerve agent surrogates and oximes were adapted to further validate their
capabilities compared to 2-PAM. The current research provides analytical results of rat
and human blood AChE and BChE and rat brain and skeletal muscle AChE activity
levels when exposed to our nerve agent surrogates (NIMP – 4-nitrophenyl isopropyl
methylphosphonate, NEMP – 4-nitrophenyl ethyl methylphosphonate, and NCMP – 4nitrophenyl cyclohexyl methylphosphonate), and novel oximes (oxime 44.08 and oxime
44.25), and 2-PAM (Worek, Thiermann et al. 2004, Worek, Aurbek et al. 2007). Kinetic
reaction rates were determined for initial inhibition, spontaneous reactivation, aging, and
oxime reactivation. Using reaction rates and standard variables determined by other
researchers, a pharmacokinetic model and calculations were hypothesized, focusing on
key body compartments involved acutely with nerve agent exposure (Munro 1994, Baker
and Sedgwick 1996, Marino, Schuster et al. 1998, van der Schans, Lander et al. 2003,
Bide, Armour et al. 2005, Whalley, McGuire et al. 2007).
Classical Versus Physiological Based Pharmacokinetic Model
Physiologically based pharmacokinetic (PBPK) models utilize a mathematical
description of the physiologic, biochemical, and physicochemical reactions that
contribute to the pharmacokinetics of the nerve agent in question (Emond, Michalek et al.
2005). In these models, the mathematical descriptors take into account the various
compartments and the variations within these compartments. Each compartment could
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have a variety of metabolizing enzyme rates, a variety of enzyme types, diffusion rates,
and accessibility requirements. There are a variety of different PBPK models utilized
based on the chemical or toxicant investigated. Considerations of which type to use must
be made based on mode of entry, elimination, dosage, enzyme induction capability, and
many other factors that may be specific to the chemical or toxicant. Chemical or toxicant
factors could include volatility, chemical structure, molecular weight, and other factors
that affect entry and interaction in the biological system. Well calculated and thorough
PBPK models can provide very accurate predictions for short term and long term studies
of pharmacokinetics (Emond, Michalek et al. 2005). The downside to precision is the
numerous parameters that must be determined experimentally to obtain the necessary
information. The more information obtained for use in the model can increase precision
and produce more accurate projections. This approach can be very informative and
useful in situations of long term exposure, but the costs could be restraining if an acute
exposure is more clinically relevant. Such is the case with nerve agent or other OP
exposures, where brain damage or death can occur in minutes or hours. In such cases,
elimination from the body, metabolism in the liver, and or interactions in non-essential
peripheral tissues is not an immediate concern. In these cases, a more simplified classical
model would be more relevant.
Classical pharmacokinetic models can provide a more cost effective look into the
interactions occurring within the simplified biological system. In the case of nerve agent
or OP poisoning, the primary concerns with nerve agent OP exposure would be the effect
on the respiratory and central nervous system. Both of these systems can easily be
reached via the circulating blood. In a classical model the metabolism of the nerve agent
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in the blood, brain, and skeletal muscle would be primary compartments of concern and
therefore the most efficient to research.
Overall Research Summary
The main objective of the research was to characterize the reactions occurring
with the sarin and VX surrogates and the novel oxime antidotes, and provide a
quantifiable comparison with 2-PAM utilizing kinetic data. In addition, the research
provided preliminary data for combined oxime therapies and the necessary protocols to
conduct such analytical testing. Finally, the kinetic data obtained from rat and human
models provided critical information for future extrapolation of human parameters in
regards to our novel oxime antidotes and possible therapeutic utilization in the future.
Chapter Two describes the experiments conducted to evaluate the best 46-series
oximes for reactivating the cyclosarin surrogate, NCMP. To date the laboratory has done
preliminary testing utilizing the novel oximes and nerve agent surrogates. Rat tissue
types tested in vitro include brain, diaphragm, and skeletal muscle. Rat and human blood
have also been tested. Measuring AChE levels in various tissues after exposure to the
novel nerve agent surrogates and novel oximes has partly been accomplished utilizing a
modified Ellman’s AChE activity assay (Ellman, Courtney et al. 1960, Worek, Diepold et
al. 1999, Worek, Mast et al. 1999, Coban, Carr et al. 2016). Similar experiments were
utilized for the NCMP testing. Some of the initial testing conducted by the laboratory
involved the sarin surrogates (NIMP and PIMP) and VX surrogate (NEMP). The oximes
showing the most reactivation for further testing with these agents were oximes 44.08 and
44.25 (Meek, Chambers et al. 2012, Chambers, Chambers et al. 2013). Oximes 44.08
and 44.25 were chosen for further kinetic testing experiments as described in the results
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of this dissertation. Any successful 46-series oximes for NCMP will also be utilized for
kinetic testing as the results are described in this dissertation.
Using a slight modification to Ellman’s AChE activity assay protocol, a novel
cyclosarin surrogate (NCMP) developed by our laboratory was tested with a different
series of novel oximes. The oximes from this series that showed the most promise for
further testing were 46.21, 46.43 and 46.49. Another, modification to the protocol was
necessary since cyclosarin and its corresponding novel surrogates are very potent
inhibitors and reactivation is hard to accomplish as demonstrated by the preliminary data
described in this dissertation and past experiments carried out by the Worek and the
Chambers labs (Worek, Eyer et al. 2007, Chambers, Chambers et al. 2013). The oximes
and NCMP were simultaneously incubated at various incubation times (15, 30, and 45
minutes). It was determined that 15 minutes was the most advantageous incubation time
to analyze AChE activity for these oximes after exposure to NCMP. In addition to these
initial experiments, information was also gathered on possible synergistic effects of
combining the most effective novel oximes and 2-PAM for reactivation after NCMP
exposure in the pooled rat brain tissue.
Chapter Three describes the AChE and BChE activity of various human, rat blood
components, and rat tissues over time for the novel surrogates and novel oximes
developed in the laboratory. The kinetic values were used to calculate the inhibition,
aging and reactivation rate constants and to compare against 2-PAM. The laboratory had
previously performed AChE and BChE experiments on intact human and rat
erythrocytes, but extensive kinetic analysis of the different enzyme sources like
erythrocyte membranes, blood plasma, brain and skeletal muscle has not been done
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(Coban, Carr et al. 2016). The current research focused on analysis of human and rat
purified erythrocyte membrane AChE and plasma AChE and BChE and rat brain and
skeletal muscle tissue AChE. The additional kinetics data provided more information on
the novel oxime reactivation capabilities and also provided a critical comparison between
human and rat models for the novel oximes. The data will provide a better perspective
when it comes to drawing conclusions to what needs to be done when transitioning from
initial rat experiments to testing clinically safe antidote doses in humans.
Chapter Four describes a hypothesized pharmacokinetic model to be used with the
current rat and human data, in conjunction with known constants from other researchers,
and tested via published case study data. The kinetic data generated from the rat and
human erythrocyte and plasma will provide the essential kinetic parameters. To complete
the data, clearance rates have yet to be determined for the novel oximes and surrogates.
This dissertation describes the findings, and provides additional experimental support for
the further development of the novel oximes as a possible improved nerve agent antidote,
that can penetrate the BBB.
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CHAPTER II
ANALYSIS OF CYCLOSARIN SURROGATE AND NOVEL OXIMES
Introduction
Chapter II describes the research with the cyclosarin surrogate, 4-nitrophenyl
cyclohexyl methylphosphonate (NCMP) and determining the best oximes for reactivating
rat brain inhibited by NCMP. The current research demonstrates a few novel oximes that
are capable of reactivating rat brain AChE after NCMP inhibition. In addition, coadministration studies with 2-PAM and the novel oximes demonstrate increased AChE
reactivation after inhibition with NCMP. This information provides initial data for a
possible combined oxime therapy with the novel oximes and 2-PAM.
Materials and Methods
Nerve agent surrogate
The cyclosarin surrogate (NCMP) was synthesized from commercially available
compounds and all reagent grade chemicals were purchased from Thermo Fisher
Scientific (Waltham, MA) or Sigma Chemical Co. (St Louis, MO). NCMP was
developed, synthesized, and characterized in the laboratory as previously described
(Meek, Chambers et al. 2012). The structure and purity were respectively confirmed
using liquid chromatography/electrospray ionization/mass spectrophotometry (LC-ESIMS) and 1H nuclear magnetic resonance (NMR). Figure 1 displays the chemical
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structure differences between cyclosarin and the corresponding nerve agent surrogate
NCMP.

Figure 1

Chemical structure of cyclosarin and NCMP

Novel oxime reactivators
The novel oximes are substituted phenoxyalkyl pyridinium oximes that have
incorporated lipophilic moieties with the expectation that the charged quaternary
ammonium will counterbalance the lipophilic moiety and impart the oxime with an
ability to cross the BBB. In addition, it is expected that the reactivating ability of the
oxime will be retained. The overall structure of this oxime series is shown in Figure 2
below and the specific substitutions are listed in Table 1 in the results section. The oxime
numbering is defined by: First number is the location of the oxime in relationship to the
quaternary nitrogen in the pyridinium ring, second number is the n describing number of
methylene’s in the methylene bridge, and the final double digit number is the sequence of
the compound in the series. The structure for 2-PAM from Sigma-Aldrich is shown in
Figure 3.
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Figure 2

General structure of substituted phenoxyalkyl pyridinium oxime

Figure 3

2-PAM chemical structure

Animals
Adult male Sprague Dawley-derived rats were used as the animal model for in
vitro screening of the oximes. All animal protocols received prior approval from the
Mississippi State University Animal Care and Use Committee.
Standard in vitro reactivation screening
The initial screening of the novel oximes for reactivation potential was conducted
with NCMP as previously described (Chambers, Chambers et al. 2013). The criterion for
moving forward was set at 5% reactivation. Three different pools of Sprague-Dawleyderived rat brains were utilized for each experiment. Each pool consisted of five rat
brains. The brains were homogenized with a Heidolph Homogenizer and diluted with
0.05 M Tris-HCl buffer (pH 7.4 at 37 oC). Specimens were stored at -80 oC until testing.
Each pooled specimen was diluted to 40 mg/ml with Tris-HCl buffer. The final
concentration (FC) for each experiment was 1 mg equivalent/ml of tissue.
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Rat brain AChE was inhibited at approximately 80 percent using a NCMP FC of 3
nM and incubated for 15 minutes at 37 oC in a shaking water bath. The inhibited rat
brain AChE was immediately reactivated using the various oximes in ethanol at a FC of
100 µM for 30 minutes at 37 oC in a shaking water bath. The samples were diluted with
TRIS-HCl buffer 1/25 to stop inhibition and reactivation. The AChE activity was
measured by adding the substrate acetylthiocholine (ATCh) at a FC of 1 mM and
incubating for 15 minutes at 37 oC in a shaking water bath. 5,5’-dithiobis(2nitrobenzoate) (DTNB) was used as the chromogen to detect activity at 412 nm on a
Thermo Scientific Biomate 3 Spectrophotometer.
Percent reactivation was determined by subtracting the total inhibition percentage,
IT, minus the total inhibition percentage after reactivation, IR, and then dividing that value
by the total inhibition percentage. Solvent controls were utilized to eliminate extraneous
activity. The criteria for continued testing was set at 5% reactivation. Equation 1 below
describes the calculation utilized.

%𝑅𝑒𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 =

%𝐼𝑇 −%𝐼𝑅
%𝐼𝑇

(1)

Simultaneous inhibition and reactivation in vitro studies
The standard in vitro reactivation protocol above was modified by adding the
NCMP and oxime simultaneously one after the other at the initial start time. The AChE
activity was measured at 15, 30, and 45 minute intervals using the modified Ellman’s
assay previously described above (Chambers, Chambers et al. 2013). The criteria for
continued testing was set at 30%.
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Combined 2-PAM and novel oxime studies
A similar protocol was used as described above, but the 100 µM FC of oxime
normally added was divided into 50 µM of 2-PAM and 50 µM of the best novel oxime.
The criterion for advancing each oxime forward for further testing was set at 40%
reactivation in the in vitro screening.
Results
The 17 novel oxime antidotes for NCMP were tested alongside 2-PAM. The best
AChE reactivation activity ranged from 4 to 5 percent and included 2-PAM, Oximes
46.21, 46.43, and 46.49 as seen in Table 1 below. Using these four oximes, simultaneous
testing was conducted. NCMP was simultaneously incubated with 2-PAM, Oximes
46.21, 46.43, or 46.49 and AChE activity was measured at 15, 30, and 45-minute time
points after incubation. Simultaneous incubation increased AChE activity for specimens
with NCMP and Oximes 46.43 or 46.49. Peak reactivation of 26 and 34 percent,
respectively, was observed for the 15-minute time point and progressively decreasing
values for the 30 and 45-minute time points. 2-PAM and Oxime 46.21 did not show any
improvement and continued to have reactivation ranging from 4 to 5 percent as
previously observed for all time points. Finally, concentrating on the successful data
from the simultaneous experiments and using a 15-minute incubation we tested the
successful oximes in combination with 2-PAM. A nearly 40 percent reactivation of
AChE was observed with Oxime 46.43 with 2-PAM and nearly 35 percent reactivation
with Oxime 46.49 and 2-PAM.
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Table 1

In vitro NCMP inhibited rat brain AChE reactivation by novel oximes.

Bold print indicates the oximes that showed best reactivation for further testing. a Number of C’s in alkyl chain (n in Figure 2). b
Substitutions on the phenoxy moiety (R in Figure 2). c 30-min incubation with 10 mM oxime following 15-min incubation with 105.5
M NCMP, n = 3, mean ± SEM. d Simultaneous incubation of 10 mM oxime and 10-5.5 M NCMP, n = 3, mean ± SEM. e This
simultaneous incubation of 10 mM novel oxime, 10 µM 2-PAM, and 10-5.5 M NCMP, n = 3, mean ± SEM.
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Discussion
All 17 novel phenoxyalkyl pyridinium oximes and 2-PAM were highly ineffective
against NCMP. This was expected considering the historical data demonstrating the
difficulty in reactivating cyclosarin inhibited AChE with the current approved US
antidote of 2-PAM (Worek, Thiermann et al. 2004, Moshiri, Darchini-Maragheh et al.
2012). Further investigation of the novel oximes and 2-PAM demonstrated increased
reactivation percentages with simultaneous exposure of rat brain AChE to NCMP and
two of the novel oximes and 2-PAM. Possible explanations for these observations were
made by reviewing the discoveries of other researchers looking into the interactions
between other nerve agents and oximes (Worek, Thiermann et al. 2004). Researchers
have suggested that differences in oxime structure, acidity, R-group attachment position
on the pyridinium ring, and also structural fit into the active site may play a role.
A number of mechanisms were considered in the interpretation of the research
results. The size of the oximes and the particular structure demonstrates a possible link to
improved reactivation. Oxime 46.43 is structurally one of the largest novel oximes that
were tested with the R-group containing only methyl groups. Oxime 46.49 was also one
of the structurally largest novel oximes tested with the R-groups containing a phenol and
methyl groups. When compared to 2-PAM and the other 14 novel oximes, these oximes
were structurally smaller then these two compounds. The exception is the oxime
containing the phthalimidyl group which is the largest structure tested of all the oximes.
This suggests that these two particular oximes may have been the perfect size for
reactivating with NCMP inhibited AChE in these conditions. In addition, structures with
R-groups containing oxygen, nitrogen, chloride, and bromine did not reactivate as well as
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the two successful oximes. These atoms may have played a role in binding activity, but
had less of a factor towards reactivation. When considering that commercial oximes like
HI6 and HLö 7 contain additional oxygen, nitrogen, and chloride elements and are very
successful at reactivating cyclosarin inhibited AChE, then the atoms mentioned may not
play a critical role at all (Worek, Thiermann et al. 2004). What may matter most is the
tertiary conformation of the protein that is dictated by the atoms present, instead of the
individual atoms themselves. The size of the two oximes most likely played an important
role in their success under these conditions. Three-dimensional modeling may be helpful
in further characterizing size relationships and interactions taking place.
The position of the oxime group on the pyridinium ring has been demonstrated by
other researchers to play a role in reactivation, with position 2 and 4 being critical (de
Jong, Verhagen et al. 1989). Worek et al. also demonstrated that position 4 is usually
associated with better organophosphate reactivation versus position 2 (Worek, Thiermann
et al. 2004). This is supported in the experimental findings with both of the oximes
located at position 4.
The addition of a second pyridinium ring to oximes has been demonstrated by
researchers to play a role in orienting some oximes into the active site of the AChE. In
particular, Ashani et al. performed active site substitutions to elucidate the interaction of
HI-6 with AChE during reactivation and discovered the importance of the second
pyridinium ring (Ashani, Radic et al. 1995). In this case, the three rings of the oxime
46.49 may play a role in orienting the oxime for improved reactivation. Amino acid
substitution testing of key elements at the active site of AChE may be beneficial in
determining the specific interaction of the oxime 46.49 with AChE, and help determine
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possible structural improvements with this NCMP antidote. Also, substitution
experiments with the previous nerve agent surrogates tested (NIMP and NEMP) and their
corresponding successful 44-series oximes may be beneficial in improving the antidotes
further (Chambers, Chambers et al. 2013).
The last significant observation is the difference in reactivation seen between
adding the oxime after the NCMP inhibition has occurred versus adding it concurrently.
One explanation to this observation is the possibility of noncompetitive or competitive
non-covalent binding of the oxime with AChE at the active site or at another location on
the enzyme. Researchers have demonstrated that allosteric changes to human AChE can
be caused by the binding of peripheral ligands noncompetitively to AChE and this
subsequently leads to modulation of paraoxon inhibition (Barak, Ordentlich et al. 1995).
Using amino acid substitutions, the researchers demonstrated that the modulation of
allosteric sites can cause conformational changes to the active site of human AChE. This
research finding could explain the possibility that the novel oximes may be interacting
with peripheral sites on the AChE and causing active site changes that temporarily
prevent inhibition by NCMP. Following the amino acid substitutions on AChE
conducted by Barak et al., this possibility could be tested for the 46-series oxime and
NCMP. A kinetic analysis may be able to demonstrate competitive inhibition as well
(Gawron and Keil 1960, Čolović, Krstić et al. 2013). Researchers have demonstrated the
use of kinetic inhibition constants to demonstrate that certain compounds can be
competitive inhibitors of AChE. This approach could be used with the 46-series oximes
and NCMP.
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A second possibility may be that the oximes are noncovalently binding to the
NCMP, and temporarily preventing it from interacting with the AChE. Researchers have
demonstrated that radiolabeled sarin can be attached to molecules in the blood with
molecular weights of 10000 and a majority of these molecules were actually AChE
(Polak and Cohen 1970). The molecular weight of the various oximes is less than 10000,
so direct binding of the oximes with NCMP is not probable.
The last observation in the data is the decreased reactivation activity observed in
the timed studies. This may be a result of normal degradation of the oximes over time
(Meek, Chambers et al. 2012, Chambers, Chambers et al. 2013). In addition, the
formation of phosphyloximes after AChE reactivation has been demonstrated to inhibit
AChE after reactivation (Worek, Szinicz et al. 2005). This inhibition could account for
the decreased reactivation over time and also the ineffectiveness of some of the many
oximes tested in initial experiments.
Conclusion
It was surprisingly unexpected to see stronger reactivation after simultaneous
incubation with NCMP and two of the better performing novel oximes, 46.43 and 46.49.
The literature provides some very important possible explanations for these observations.
Our results further emphasize the importance of oxime size, location of the R-group
attachment on the phenoxy ring, and the possible importance of additional phenoxy rings
when orienting the active site.
Also the success of our combined oxime experiments with 2-PAM and oxime
46.43 or oxime 46.49, helps support the possibility of future such experiments. In
particular combined oxime experiments with 2-PAM and the other successful oximes
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44.08 and 44.25 could be useful in developing actual in vivo therapies in the future for
reactivating the sarin and VX surrogates (Chambers, Chambers et al. 2013).
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CHAPTER III
KINETIC COMPARISON
Introduction
Testing of nerve agent exposure and corresponding antidote efficacy is primarily
accomplished via in vitro and in vivo animal models (Thiermann, Kehe et al. 2007). The
primary cost effective animal model is centered on the Sprague Dawley-derived rat or
other similar research rats. Actual nerve agent testing on humans is limited to blood
components (Worek, Eyer et al. 1998). Kinetic testing of enzymes provides a
quantitative means to evaluate the effects of various substrates, inhibitors, and
reactivators on the active site of an enzyme (Valiveti, Bhalerao et al. 2015). To improve
data extrapolation from rat to humans, a comparative kinetic analysis was performed to
provide the initial information for translating antidote dosing for humans via a future
pharmacokinetic model (Worek, Reiter et al. 2002, Eyer, Szinicz et al. 2007).
To accomplish the kinetic analysis rat and human blood were processed to
analyze acetylcholinesterase (EC 3.1.1.7, AChE) on the erythrocyte membrane, and
AChE and butyrylcholinesterase (EC 3.1.1.8; BChE) suspended in the plasma. In
addition, rat brain and skeletal muscle (SKM) were also processed to analyze AChE in
these tissues. A modified Ellman’s AChE and BChE activity assay using a 96-well plate
was developed and utilized to determine the necessary kinetic values. Inhibitors used
were a VX nerve agent surrogate (4-nitrophenyl ethyl methylphosphonate; NEMP) and a
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sarin nerve agent surrogate (4-nitrophenyl isopropyl methylphosphonate; NIMP). AChE
and BChE reactivators tested were pralidoxime chloride (2-PAM), and novel oximes
44.08 and 44.25. The AChE and BChE kinetic values obtained from the experiments
include the maximum velocity (Vmax), the apparent Michaelis-Menten (Kmapp) constant,
the association constant (KA), the rate of phosphorylation (kp), the rate of inhibition (ki),
the rate of reactivation (kr), the rate constant for aging (ka), and the rate constant for
spontaneous reactivation (ks).
The kinetic values provided important measurements of enzyme activity in the
tested specimens and allowed for points of comparison (Voet and Voet 2011). The
Michaelis constant (Km) is a measure of the affinity of the enzyme for its substrate as
long as the k2 is less than k-1. A small Km value means an enzyme reaches maximal
catalytic efficiency at low substrate concentrations. It is the substrate concentration at
which the reaction rate is half of Vmax. The Vmax value is the maximum rate achieved
when enzyme concentration is saturated. In the presence of an inhibitor the Km is called
Kmapp, because the inhibitor alters the true Km and Vmax values. Though the Km and Vmax
values are altered in the presence of an inhibitor, their true underlying values are still the
same without the inhibitor. The Kmapp varies based on the inhibitor and inhibitor
concentration. The rate of inhibition ki describes the inhibition rate of an enzyme in the
presence of specific inhibitors and can be described as ki for a forward reaction and k-i for
a reverse reaction. The Ki is the inhibition constant that describes the forward and
reverse inhibition rates, where Ki = ki/k-i. For the inhibition rates, the higher the number
the faster the rate of inhibition. The KA is the association constant that describes the
strength of the enzyme inhibitor association (Carr and Chambers 1996). The higher the
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number the greater the association. The kp is the phosphorylation rate of the enzyme
forming the inhibited enzyme. The higher the number, the faster the rate of
phosphorylation of the enzyme by the inhibitor. The binding affinity to the active site
and the rate of phosphorylation, respectively KA and kp, together determine the
bimolecular rate constant, ki, which is the measurement of the inhibitory power of an
inhibitor (Coban, Carr et al. 2016). The phosphylated enzyme is susceptible to
spontaneous hydrolysis of the phosphylated enzyme resulting in spontaneous reactivation
and the associated ks rate (Worek, Thiermann et al. 2004). The phosphylated enzyme is
also susceptible to spontaneous hydrolysis of one alkyl-ester bond and the resulting
negatively charged residue that is resistant to nucleophile attack by oximes or
spontaneous reactivation, and is termed aged with its corresponding aging rate constant
ka. Aged enzyme is permanently inhibited. The higher the ks and ka value the faster the
rate.
This chapter describes the experimental procedures used to conduct the kinetic
experiments, describes the findings of the analyses and discusses the results.
Materials and Methods
Nerve agent surrogates
The sarin surrogate (4-nitrophenyl isopropyl methylphosphonate; NIMP) and VX
surrogate (4-nitrophenyl ethyl methylphosphonate; NEMP) were synthesized from
commercially available compounds by Dr. Howard Chambers and all reagent grade
chemicals were purchased from Thermo Fisher Scientific (Waltham, MA) or Sigma
Chemical Co. (St Louis, MO) (Meek, Chambers et al. 2012). Figure 4 depicts the
chemical structure of the real nerve agents and the nerve agent surrogates.
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Figure 4

Chemical structures of nerve agents and surrogates

Side by side chemical structure comparison between (A) sarin and the corresponding
surrogate NIMP and (B) VX and the corresponding surrogate NEMP.
Novel oxime reactivators
The novel oximes are substituted phenoxyalkyl pyridinium oximes and have
incorporated lipophilic moieties with the expectation that the charged quaternary
ammonium will counterbalance the lipophilic moieties and impart the oxime with an
ability to cross the BBB (US Patent 9,277,937). In addition, it is expected that the
reactivating ability of the oxime will be retained. These were synthesized by Dr. Howard
Chambers. The overall structure of this oxime series is shown in Figure 5.A. and the
specific substitutions are shown in Figure 5.B.
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Figure 5

General chemical structure of novel oximes and R-group

(A) General structure of substituted phenoxyalkyl pyridinium oximes. R can represent a
variety of chemical substitutions on the phenoxy moiety and n indicates the number
carbons in the alkyl chain. For the compounds tested n = 4. Oxime 44.08 and oxime
44.25 are also referred to respectively as MSU 01 and MSU 20. (B) Chemical structure
of the substitutions for the chemicals tested. The first digit of the code number is the
location of the oxime in relationship to the quaternary nitrogen in the pyridinium ring, the
second digit represent the n in the structure and denotes the number of methylene groups
in the chain, and the last double digit is the sequence number of the compound in the
series.
Animals
Adult male Sprague Dawley-derived rats (250-300 g) were housed in AAALAC
accredited facilities with temperature controlled environments and 12 h dark-light cycle.
LabDiet and tap water were provided ad libitum. All animal protocols received prior
approval from the Mississippi State University Animal Care and Use Committee. All
blood samples were collected via cardiac puncture and collected in
ethylenediaminetetraacetic acid (EDTA) tubes (Parasuraman, Raveendran et al. 2010).
All rat brain and skeletal muscle specimens were homogenized in a 15 ml ground glass
Pyrex homogenizer and washed with Tris buffer, described below. Final experimental
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concentration of 1 mg/ml of tissue was made with Tris buffer. Sample pools consisted of
5 different rats.
Human Blood
All human samples were collected at Columbus Air Force Base Medical Group
(Columbus, MS) by medical laboratory technicians. Human blood samples were
collected in EDTA tubes, and were ready to be discarded by the laboratory. Samples
were de-identified and no patient demographics or information was provided. All human
protocols were reviewed and approved by the IRBs at Mississippi State University and at
Keesler Air Force Base research center. Sample pools consisted of 5 different human
specimens. 20 human samples were collected in all and 4 pools created.
Buffers and Reagents
Sodium phosphate wash buffer (SPB) was made at 100 mM at pH 7.4. Hypotonic
hemolysis buffer (HPB) was made at 6.7 mM at pH 7.4. The SPB and HPB were used
for all blood experiments. Tris HCl buffer was made at 0.05 M at pH 7.7 at 25 oC which
results in a pH of 7.4 at 37 oC. The Tris HCl buffer was used for rat brain and skeletal
muscle experiments. The substrates acetylthiocholine (ATCh) and butyrylthiocholine
(BTCh) were made at 0.1 M at pH 4.5. ATCh and BTCh were aliquoted into 1 ml
conical tubes and frozen at 4 oC until testing. The chromagen DTNB was made at 0.03
M. The DTNB was aliquoted into 5 ml glass vials and frozen at 4 oC until testing. The
cholinesterase (ChE) inhibitor eserine sulfate was made at 10-3 M. The eserine sulfate
was aliquoted into 1 ml conical tubes and frozen at 4 oC until testing.
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AChE and BChE Preparation
Blood specimens were centrifuged for 10 minutes at 1500xg at 4 oC (Eppendorf
Centrifuge 5702R, A-4-38 rotor). The plasma was removed, aliquoted, pooled, and
stored at -80 oC until testing. Erythrocytes were washed with SPB (0.1M, pH 7.4) and
then lysed with HPB (6.7 mM, pH 7.4). The erythrocyte solution was ultracentrifuged to
remove hemoglobin for 30 minutes at 4 oC (Beckman Coulter Avanti Centrifuge, JA-20
rotor). The supernatant was discarded and the pelleted samples were pooled. The lysed
erythrocytes, now ghosts, were washed and returned to original volume with SPB (0.1 M,
pH 7.4). A 15 ml ground glass Pyrex homogenizer was used to thoroughly resuspend and
mix samples and then aliquot 250 μl into conical tubes which were stored at -80 oC until
testing (Dodge, Mitchell et al. 1963, Worek, Reiter et al. 2002).
Rat cerebral cortex and medulla oblongata and skeletal muscle were ground with
a Polytron PT 10-35 Grinder and then homogenized with a Heidolph Homogenizer with a
Teflon pestle in cold 0.05 M Tris-HCl buffer (pH 7.4 @ 37C) at a concentration of 40
mg/ml for brain or 100 mg/ml for skeletal muscle. The homogenate was filtered through
glass wool or gauze. Five rat samples were utilized per pooled sample. Samples were
aliquoted into 4 ml glass vials and maintained at -80 oC until testing. Prior to testing, rat
brain and skeletal muscle were washed with Tris buffer to reduce turbidity. To
accomplish this the specimens were centrifuged for 5 minutes at 5000xg and the
supernatant was discarded (Eppendorf Centrifuge 5415C, F-45-18-11 rotor). The sample
was returned to the original volume with Tris buffer. All testing was performed on the
tissue pellet. After washing the samples were diluted appropriately with Tris buffer for a
final testing concentration of 1 mg equivalent/ml per well.
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AChE and BChE Substrate Kinetics Procedure
The sample analysis was conducted using a 96-well plate with a final testing
volume of 300 µl per well. Samples were diluted to obtain a consistent absorbance of
approximately 0.3 units. ATCh and BTCh concentrations were used to produce a range
of enzyme activity in the experimental wells. The chromagen DTNB was added to the
testing wells for a final concentration (FC) of 0.002 M. In addition to experimental wells,
control wells were also included. Eserine sulfate, a ChE inhibitor, was added to the
appropriate blank wells to obtain a FC 10-5 M and displayed absence of ChE activity to
allow correction of non-ChE-mediated absorbance. Ethanol vehicle was added to the
appropriate control wells to demonstrate maximum ChE activity. The appropriate
substrate was added to the control wells for a FC of 2.5 mM. The experimental wells had
a range of substrate concentrations from 0.02 mM to 2.5 mM. Enzyme activity was
measured using a modified Ellman’s assay as previously described (Ellman, Courtney et
al. 1960, Carr and Chambers 1996, Chambers, Chambers et al. 2013). The same protocol
was utilized for rat brain and skeletal muscle substrate kinetics, but the final testing
concentration was 1 mg equivalent/ml and the 96-well plate volume was 200 µl per well.
For each concentration and control, the velocity was calculated. The velocities
were then used to formulate a Lineweaver Burk plot with the reciprocal of each velocity
on the y-axis and the reciprocal of each ATCh (BTCh) concentration on the x-axis as
depicted in Figure 6. The resulting data were used to formulate a linear line with the
coefficient of determination statistic (R2-value) greater than 0.9 for acceptable results.
The Kmapp = -slope and Vmax = x-intercept (Hofstee 1959, Carr and Chambers 1996).
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Figure 6

Lineweaver Burk plots for ATCh and BTCh substrate hydrolysis.

Lineweaver Burk plots used for determination of (A) ATCh and (B) BTCh substrate
hydrolysis kinetics by AChE and BChE respectively.
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AChE and BChE Inhibition Kinetics Procedure
The sample analysis for blood fractions was conducted using a 96-well plate with
a final testing volume of 300 µl per well. Samples were diluted to obtain an absorbance
of approximately 0.3 units. NEMP and NIMP concentrations were selected to effectively
produce a range of 10 to 90 percent enzyme inhibition as depicted in Table 2 below. The
chromagen DTNB was added to the testing wells for a FC of 0.002 M. Eserine sulfate,
the ChE inhibitor, was added to the appropriate blank wells to obtain a FC 10-5 M. The
substrate was added to the testing wells for a FC of 0.0025 M. Enzyme activity was
measured using a modified Ellman’s assay as previously described (Chambers, Chambers
et al. 2013). Kinetic readings were performed at 0, 1, 2, 3, 4, and 5-minute time points.
At each time point 12 continuous kinetic readings of the 96-well plate were obtained and
enzyme activity was measured as mentioned above. The same protocol was utilized for
rat brain and skeletal muscle substrate kinetics, but the final testing concentration was 1
mg equivalent/ml of tissue and the 96-well plate volume was 200 µl per well.
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Table 2

NEMP and NIMP inhibition concentrations

Eight concentrations of NEMP and NIMP were utilized to obtain 10% to 90% inhibition
for rat and human AChE and BChE blood sources as displayed in the table below.
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For each concentration and control, the velocity of each incubation period was
calculated. For each preincubation time, the fraction of AChE or BChE velocity left was
calculated by dividing the AChE or BChE velocity following inhibition ([E]t) by the
original uninhibited velocity ([E]0) as described in the Equation 2 below.

[𝐸]𝑡
[𝐸]0

= 𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 𝑏𝑦 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒

(2)

Using the linear regression of the natural log (ln) of the [E]t/[E]0 value as a
function of time provided a line at each inhibitor concentration with slope equal to -kapp
as described with Equation 3 below.

[𝐸]

ln [𝐸] 𝑡 = −𝑘𝑎𝑝𝑝 𝑡
0

(3)

The -kapp value was the apparent rate of AChE or BChE phosphorylation. A
double reciprocal plot of the kapp as a function of the inhibitor concentration, depicted in
Figure 7 below, provided a line equation to determine the necessary kinetic values.
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Figure 7

Lineweaver Burk plots for inhibition kinetics

Lineweaver Burk plots used for determination of inhibition kinetics. Represented are
NEMP inhibition of (A) rat plasma AChE, (B) rat SKM AChE, and (C) human plasma
AChE.
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From the line equation the kinetic values are determined with, the slope equal to
1/ki, the y-intercept equal to 1/kp, and the x-intercept equal to -KA, as seen in Equation 4
below (Segel 1975, Carr and Chambers 1996, Worek, Thiermann et al. 2004).

(4)

𝑦 = 𝑚𝑥 + 𝑏
𝑆𝑙𝑜𝑝𝑒 𝑚 =

1
𝑘𝑖

𝑦 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =

1
𝑘𝑝

x−𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 = −𝐾𝐴

Equation 5 below describes the overall reaction and summarizes the basis of the
calculations to obtain the necessary kinetic values. Symbols are defined as: [E] is
concentration of free enzyme, [I] is concentration of free inhibitor, [EI]R is the reversible
enzyme-inhibitor complex, [EI]I is the irreversible phosphorylated enzyme-inhibitor
complex, and [EI]a is the aged enzyme-inhibitor complex. The reaction rates were
previously described. Equation 6 assumes the reaction primarily flows forward with the
kp and not reverse with the k-1. Equation 7 describes the rates associated with inhibition,
while Equation 8 demonstrates the relationship between all rates for the reaction scheme.
The KD rate constant was not previously described and represents the dissociation
constant between the inhibitor and enzyme.
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𝑘𝑟
𝑘1
𝑘𝑝
→
[𝐸] + [𝐼] ↔ [𝐸𝐼]𝑅 → [𝐸𝐼]𝐼
→
𝑘𝑎
𝑘−1

[𝐸] + [𝑂𝑥𝑖𝑚𝑒 𝐼]
[𝐸𝐼]𝑎

(5)

Assuming 𝑘𝑝 ≪ 𝑘−1

(6)

(𝐾𝐴 )(𝑘𝑝 ) = 𝑘𝑖

(7)

𝑘𝑖 = (𝐾𝐴 )(𝑘𝑝 ) =

𝑘𝑝
𝐾𝐷

=

(𝑘1 )(𝑘𝑝 )
𝑘−1

(8)

AChE and BChE Reactivation Kinetics Procedure
The sample analysis for blood fractions was conducted using a 96-well plate with
a final testing volume of 300 µl per well (200 µl per well for rat brain and skeletal
muscle). Enzyme activities were inhibited by about 90 percent utilizing an appropriate
concentration of NEMP or NIMP. Inhibited erythrocyte AChE and rat brain and skeletal
muscle AChE samples were washed two times with the appropriate buffer by
centrifugation and removal of supernatant to remove excess inhibitor and then
resuspension with buffer. Centrifugation was done at 5 minutes at 5000xg and samples
were returned to their original volumes (Eppendorf Centrifuge 5415C, F-45-18-11 rotor).
Since AChE and BChE are suspended in the plasma, removing the inhibitor via
centrifugation was not possible. To decrease or stop additional inhibition, the plasma
was diluted. Pre-testing was done to determine the minimal volume of sample and
inhibitor necessary for optimal inhibition, and the minimal dilution necessary to eliminate
or reduce further inhibition without compromising overall enzyme activity and
subsequent absorbance. The amount of dilution varied by pool of plasma, enzyme being
tested (AChE or BChE), or species (rat or human).

The inhibited sample was split into

five equal portions. To two portions, 30 µl (10 µl for rat brain and skeletal muscle) of
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ethanol was added per ml to measure spontaneous reactivation and aging. To three
separate portions, oximes were added to measure reactivation, FC 0.3 mM (2-PAM,
oxime 44.08, and oxime 44.25). For rat brain and skeletal muscle, oximes were added at
FC 0.1 mM. Utilizing the same concentration of chromagen, eserine sulfate, and
substrate listed above, kinetic readings were performed at 0, 15, 30, 45, and 60-minute
time points by withdrawing a sample from each portion and assaying. At each time point
12 continuous kinetic readings of the 96-well plate were performed and enzyme activity
was measured as mentioned above.
Determination of the ratio of AChE (BChE) activity at each time interval was
calculated by dividing the AChE (BChE) activity in the inhibited samples by the
matching control activity as seen in Equation 9 below (Kitz and Wilson 1962).

[𝐸]𝑡
[𝐸]0

= 𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 𝑏𝑦 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒

(9)

Using the natural log of the ratio of inhibited versus control activity (y-axis) at
each time point (x-axis), the various rate constants described below were obtained (kr, ks,
ka) with the slope of the best fit line with R2-value no less than 0.9. All rate constant
variables were on the y-axis and the time points were on the x-axis. First order rate
constants were calculated from linear regression of the natural log (ln) of the ratio of
AChE (BChE) activity as a function of time. Using the vehicle (control) plots, the
spontaneous reactivation (s) rate constant, ks, was estimated from the slope of the line
described by Equation 10 below (Kitz and Wilson 1962).
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[𝐸]

ln [𝐸] 𝑡 = 𝑘𝑠 𝑡
0

(10)

Using the oxime reactivation plots, the oxime reactivation rate (r) constant, kr,
was estimated from the slope of the line described by Equation 11 below (Kitz and
Wilson 1962).

[𝐸]

ln [𝐸] 𝑡 = 𝑘𝑟 𝑡
0

(11)

Using the oxime reactivation plots from the 2-PAM aging data, the aging rate (a)
constant, ka, was estimated from the slope of the line described by the Equation 12 below
(Kitz and Wilson 1962).

ln (1 −

[𝐸]𝑡
[𝐸]0

) = 𝑘𝑎 𝑡

(12)

Aging was determined by incubating a portion of the inhibited sample with the
oxime reactivator 2-PAM at a concentration determined in preliminary experiments to
reactivate 100% of AChE(BChE) at each of the set time points (15, 30, 45, and 60
minutes) and calculating if any AChE(BChE) was not reactivated by subtracting from 1.
The percent not reactivated was considered the aged AChE(BChE). The difference
between the reactivation and aging rate constant provided the true reactivation rate
constant.
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Statistical Analysis
Data were analyzed using Sigma Plot software on a PC. Blood sample data were
analyzed by two-way or three-way ANOVA when appropriate, p ≤ 0.001. Pairwise
comparisons were made with Holm-Sidak method, p < 0.05. Rat brain and skeletal
muscle data were analyzed by one-way ANOVA when appropriate, p ≤ 0.001. Pairwise
comparisons were made with Holm-Sidak method, p < 0.05. All data with comparisons
of two values were analyzed with t-test when appropriate, p < 0.05. When distribution
was not normal and variances were unequal, the data were analyzed nonparametrically
with Mann-Whitney Rank Sum Test (T = 6-18, n1 = 3, n2 = 3-4, P < 0.05).
Results
Nerve agent surrogate concentrations needed for AChE and BChE inhibition are
presented in Table 3 below. The data demonstrated differences between IC50
concentrations of rat and human and NEMP and NIMP. Rat plasma AChE and BChE
had significantly lower NEMP and NIMP IC50 concentrations compared to their
corresponding human AChE and BChE samples. All other rat and human comparison
differences were not statistically significant. When comparing NEMP versus NIMP for
different specimen types, only half of the specimens demonstrated significant differences.
Human plasma AChE and BChE, rat plasma BChE, and rat skeletal muscle AChE
demonstrated NIMP IC50 concentrations that were significantly higher than
corresponding NEMP IC50 concentrations.
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Table 3

Median inhibition concentrations

The original concentration ranges from table 2 above were used to calculate the
designated median inhibition concentration (IC50) values (mean ± SEM) in Table 3. Data
transformation were not necessary due to the linearity of the original data. IC50 values
were analyzed statistically for differences between human and rat specimens and between
nerve agent surrogates NEMP and NIMP. For blood specimens a two-way ANOVA was
conducted that examined the effect of species differences and inhibitor type on IC50
concentrations. There were statistically significant differences between effects of
different species and inhibitor type on IC50 concentrations, F = (1415, 1294) = 546, p ≤
0.001. Pairwise comparisons were made with Holm-Sidak method for all ANOVA
analyses. For rat brain and skeletal muscle specimens a two-sided t-test was performed, p
≤ 0.05, (*) indicates statistically significant differences between rat and human blood
specimen types, (Δ) indicates inhibitor, NEMP or NIMP, with a significantly different
IC50 concentration
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Substrate hydrolysis by AChE or BChE was analyzed using Vmax and Kmapp
kinetic values as depicted in Table 4 below. The Vmax for human plasma AChE was
significantly higher than the corresponding rat samples, but the p-value was greater than
the p < 0.05 cutoff (p = 0.07). The closeness of the actual p-value to the cutoff, provided
support for accepting the difference as significant. The Vmax for rat plasma BChE was
significantly higher than the corresponding human samples.
The Kmapp for human erythrocyte AChE and plasma BChE were significantly
higher than the corresponding rat samples, but the p-values were greater than the p < 0.05
cutoff (both p = 0.06). The closeness of the actual p-value to the cutoff, provided support
for accepting the difference as significant.

The Kmapp for rat plasma AChE was

significantly higher than the corresponding human sample. All other Vmax and Kmapp
comparisons between human and rat blood samples did not indicate significant
differences between the species.
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Table 4

Substrate Hydrolysis

In vitro ATCh and BTCh hydrolysis respectively by AChE and BChE from human and
rat blood, brain and skeletal muscle. For comparing only human and rat blood specimen
types a two-sided t-test was performed, n = 3-4, mean ± SEM, p ≤ 0.05, (*) indicates
statistically significant differences between rat and human blood specimen types
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Inhibition kinetics of nerve agent surrogates with human and rat AChE and BChE
sources are depicted in Table 5 below. The data demonstrated differences in the
inhibition kinetic values for rat and human specimens. The KA values for rat NEMP
inhibited erythrocyte AChE and plasma AChE and BChE were significantly higher than
the corresponding human KA values. The KA value for NIMP inhibited rat erythrocyte
AChE was significantly higher than the corresponding human samples. When comparing
inhibitors using KA values, rat plasma AChE and BChE and human erythrocyte AChE
had significantly higher values for NEMP versus NIMP (respectively p = 0.02, 0.04,
0.006). Rat erythrocyte AChE had KA values significantly higher for NIMP versus
NEMP (p < 0.001). All other rat and human blood specimen type comparisons did not
have statistically significant differences.
The kp value differences for all NEMP and NIMP inhibited human and rat
specimen types were not statistically significant. When comparing inhibitors using kp
values, rat plasma AChE had significantly higher values for NIMP versus NEMP (p =
0.002).
The ki values for NEMP and NIMP inhibited rat erythrocyte AChE were
significantly higher than human erythrocyte AChE. The ki value for NIMP inhibited rat
plasma AChE was significantly higher than human plasma AChE. When comparing ki
values between NEMP and NIMP, rat and human erythrocyte AChE had significantly
higher ki values with NEMP versus NIMP (both p < 0.001). The opposite occurred with
rat plasma AChE which had significantly higher ki values with NIMP versus NEMP (p <
0.001). Rat brain and skeletal muscle AChE also had significantly higher ki values with
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NEMP versus NIMP (respectively p = 0.07 and 0.02). Though the p-value for rat brain
AChE was above the p < 0.05 cutoff, the close proximity was acceptable.
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Table 5

Inhibition

In vitro AChE and BChE inhibition by NEMP or NIMP. For blood specimens a two-way ANOVA was conducted that examined the
effect of species differences and inhibitor type on the KA, kp, or ki. There were statistically significant differences between effects of
different species and inhibitor type on KA, kp, or ki. For KA statistic, F = (0.04, 153) = 15, p ≤ 0.001, for kp statistic F = (1, 4) = 4, p =
0.009, for ki statistic, F = (7, 112) = 9, p ≤ 0.001. Pairwise comparisons were made with Holm-Sidak method for all ANOVA
analyses, p ≤ 0.05. For rat brain and skeletal muscle specimens a two-sided t-test was performed, n = 3-4, mean ± SEM, p ≤ 0.05, (*)
indicates statistically significant differences between rat and human blood specimen types, (Δ) indicates inhibitor, NEMP versus
NIMP, with a significantly different ki value
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Oxime reactivation kinetics of AChE or BChE inhibited by surrogates are
represented in Table 6 and 7 below, respectively NEMP and NIMP. The data
demonstrated in vitro AChE and BChE inhibition respectively by NEMP or NIMP and
subsequent reactivation by various oximes. When comparing rat and human samples,
only NEMP inhibited rat plasma AChE reactivated by 2-PAM and oxime 44.08 displayed
significantly lower reactivation rates compared to corresponding human specimens. All
other differences in rat and human comparisons did not indicate significance.
When comparing oximes, nearly all comparisons between oximes were not
significantly different among the various rat and human enzyme sources. One exception
was NIMP inhibited human erythrocyte AChE where 2-PAM had significantly higher
reactivation rates compared to oxime 44.08. The other exception was NEMP and NIMP
inhibited rat brain AChE where 2-PAM had significantly higher reactivation rates
compared to oxime 44.08 and 44.25. When looking at overall oxime comparisons
utilizing all the NEMP and NIMP inhibited rat and human blood sample data, 2-PAM
had significantly higher reactivation rates versus oxime 44.08 and oxime 44.25 (p =
0.004). When using the same data, no significant differences were seen between oxime
44.08 and oxime 44.25 (p = 0.199). When looking at NEMP and NIMP inhibited rat
brain AChE alone, 2-PAM had significantly higher reactivation rates versus oxime 44.08
and 44.25 (p < 0.001). When looking at NEMP and NIMP inhibited rat skeletal muscle
AChE alone, there were no statistically significant differences between the oximes. In
addition, NIMP inhibited rat erythrocyte AChE demonstrated 2-PAM had significantly
higher reactivation rates versus oxime 44.08.
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When comparing NEMP versus NIMP in terms of reactivation rates of the oximes
for only the blood samples, significant differences were seen with 2-PAM which had
significantly higher reactivation rates for NEMP versus NIMP (p = 0.02). Oximes 44.08
and 44.25 had significantly higher reactivation rates for NIMP versus NEMP
(respectively p = 0.01 and p = 0.03). When looking at rat brain AChE alone, NEMP had
significantly higher reactivation rates for all the oximes versus NIMP (p < 0.001). When
looking at rat skeletal muscle AChE alone, NIMP had significantly higher reactivation
rates for all the oximes versus NEMP (p < 0.001).
When comparing differences between oximes for all blood samples, rat plasma
BChE demonstrated oxime 44.25 had significantly lower reactivation rates versus 2-PAM
(p = 0.02). For rat and human erythrocyte AChE oxime 44.25 had significantly higher
reactivation rates versus oxime 44.08 and lower reactivation rates versus 2-PAM
(respectively p = 0.004, 0.016 for rat and p = 0.001, 0.003 for human).
Aging and spontaneous reactivation of AChE or BChE inhibited by surrogates are
depicted in Table 6 and 7 below, respectively NEMP and NIMP. The data demonstrated
in vitro AChE and BChE inhibition by NEMP or NIMP and subsequent aging and
spontaneous reactivation over an hour time frame. All NEMP and NIMP inhibited rat
and blood samples had aging and spontaneous reactivation rates that were not
significantly different than corresponding human blood samples, except for NEMP
inhibited rat plasma AChE which had a significantly lower spontaneous reactivation rate
compared to the corresponding human plasma AChE (p < 0.001).
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Table 6

NEMP Inhibition and Oxime Reactivation

In vitro AChE and BChE inhibition by NEMP and reactivation by various oximes. For
blood specimens a three-way ANOVA was conducted that examined the effect of species
differences, different oximes, and different inhibitor types on the kr. There were
statistically significant differences between effects of different species, oximes, and
inhibitor on kr. F = (14, 10, 0.07) = 0.2, p ≤ 0.001. Pairwise comparisons were made with
Holm-Sidak method for all ANOVA analyses when indicated, p ≤ 0.05. For rat brain and
skeletal muscle specimens a one-way ANOVA was conducted comparing oximes, F = 19,
p ≤ 0.003. For ka and ks values for rat and human blood specimens a two-sided t-test was
performed, n = 3-4, mean ± SEM, p ≤ 0.05, (*) indicates statistically significant
differences between rat and human blood specimen types, (P) indicates significant
difference between 2-PAM and one or both of the novel oximes as indicated
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Table 7

NIMP Inhibition and Oxime Reactivation

In vitro AChE and BChE inhibition by NIMP and reactivation by various oximes. For
blood specimens a three-way ANOVA was conducted that examined the effect of species
differences, different oximes, and different inhibitor types on the kr. There were
statistically significant differences between effects of different species, oximes, and
inhibitor on kr. F = (14, 10, 0.07) = 0.2, p ≤ 0.001. Pairwise comparisons were made with
Holm-Sidak method for all ANOVA analyses, p ≤ 0.05. For rat brain and skeletal muscle
specimens a one-way ANOVA was conducted comparing oximes, F =132, p ≤ 0.001.
For ka and ks values for rat and human blood specimens a two-sided t-test was performed,
n = 3-4, mean ± SEM, p ≤ 0.05, (*) indicates statistically significant differences between
rat and human blood specimen types, (P) indicates significant difference between 2-PAM
and one or both of the novel oximes as indicated
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Discussion
The data demonstrated important differences between rat blood AChE and BChE
versus human blood AChE and BChE when inhibited with NEMP and NIMP, and
subsequent reactivation with 2-PAM and novel oximes.
NEMP and NIMP inhibitory concentrations: For half of the enzyme sources the
NIMP IC50 concentrations were higher compared to the NEMP concentrations. This
indicates that the VX surrogate is more potent than the sarin surrogate for these
conditions and sample types. This is consistent with the potency of real sarin and VX,
where VX is also more potent than sarin when tested against human erythrocyte AChE
(Worek, Thiermann et al. 2004). The data also supported previous observations
published for NEMP and NIMP, where NEMP is also more potent than NIMP (Meek,
Chambers et al. 2012).
Human plasma AChE and BChE sources had greater NEMP and NIMP IC50
concentrations compared to corresponding rat plasma AChE and BChE sources. This is
an important observation when considering nerve agent surrogate dosing in rat models
and expectations in human modeling. This indicates rat samples may be more sensitive
to NEMP and NIMP versus humans which suggests that the rat information may be
conservative for human predictions. This could partly be explained by published
research data that demonstrated rat blood AChE activity is double the activity observed in
the rat brain (Habila, Inuwa et al. 2012). This may suggest that there are larger AChE
concentrations in the rat blood and therefore proportionally larger AChE concentrations
in the human blood. In addition, the variations in concentration may be associated with
the balance of AChE and BChE in the blood and the variability in binding affinity of
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AChE and BChE (Juul 1968). Another difference to consider between species is the ChE
activity differences between rat males and females. Researchers have demonstrated
higher concentrations of BChE in humans versus rat males (2x) and females (6x)
(Ecobichon and Comeau 1973).
Substrate kinetics: The data on substrate kinetics provided further insight into
what NEMP and NIMP concentration differences there are between rat and human AChE
and BChE sources. The differences seen in the necessary inhibitory concentrations of
NEMP and NIMP, and the variability among species kinetic rates may be a result of the
composition of the AChE and BChE present in rat and human blood and rat brain and
skeletal muscle. Researchers have identified 12 ChE isoenzymes which catalyze the
same reaction but differ in their chemical properties or amino acid sequence (Juul 1968,
Wilkinson 1970). The identified ChE isoenzymes were characterized into three
components of AChE or BChE, defined by their binding affinity (low, medium, and
high), in a variety of blood and solid tissues which can play a role in Kmapp and Vmax
values (Juul 1968, Dave, Syal et al. 2000). In human serum, there are three components
of BChE present with different binding affinities versus the two components in rat serum.
In this case the rat serum is missing the high-affinity component. It is reasonable to think
that having more components equates to greater binding affinity or a lower Kmapp, but
composition alone may not define binding affinity fully. The concentration of the
components could also play a role and provide further variability between species. This
latter explanation could account for the higher Kmapp value in human plasma BChE when
a lower Kmapp would be expected compared to the corresponding rat values. In this case,
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the more components of human plasma BChE with a broader affinity spectrum did not
translate to a stronger BChE binding affinity.
Human erythrocytes have two components of AChE present versus the three
components in rat erythrocytes (Juul 1968, Dave, Syal et al. 2000). In this case the
human plasma is missing the mid-affinity component. In the current experiment, the
human erythrocyte AChE maintains a higher Kmapp value compared to the corresponding
rat values, despite missing a component. So again the concentration of each component
may play a role in overall binding affinity and therefore Kmapp. There is no research data
identifying the composition of plasma AChE, but since rat plasma AChE has a higher
Kmapp value, then the human plasma may be missing the high affinity component. The
composition makeup and concentration of the components for the analyzed specimens
could provide further insight into the observations seen.
Binding affinity may also be affected by the size of the active site gorge, where
AChE is more narrow and BChE is larger (Pohanka 2014). The later could allow for
greater interactions with a variety of compounds and therefore increased affinity through
increased interactions (Masson and Lockridge 2010). Kinetic research conducted on
human plasma BChE and erythrocyte AChE, demonstrated lower Kmapp values for plasma
BChE versus erythrocyte AChE (Kato, Hashimoto et al. 2000). The current study
demonstrates the same finding for rat plasma AChE and BChE where the latter has a
lower Kmapp value (p < 0.05).
The Kmapp value for human erythrocyte AChE was determined to be 0.10 mM,
which was similar to published data of 0.18 mM and 0.08 mM (Ciliv and özand 1972,
Kamal, Greig et al. 2000). The Kmapp value for human serum BChE was determined to be
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0.1 mM, which was similar to published data of 0.1 and 0.2 mM (Simeon-Rudolf, Reiner
et al. 1999). The Kmapp value for rat brain AChE was determined to be 0.148 mM, which
was similar to the published data of 0.110 mM and 0.055 mM, and also similar to rat
heart AChE 0.100 mM (Moss and Fahrney 1978, Watts and Hoogmoed 1984, Carr and
Chambers 1996). The other sources of AChE and BChE did not have any published
values. Overall the affinity compositions of human and rat AChE and BChE can be
useful tools in defining the differences seen in inhibition and reactivation since Vmax and
Kmapp are important factors in the calculation of these kinetic values (Carr and Chambers
1996, Worek, Thiermann et al. 2004).
Inhibition Kinetics of AChE and BChE: The comparison between rat and human
blood continues by looking at the bimolecular rate constant, which is defined here by the
ki. The ki describes the inhibitory power of the nerve agent surrogates NEMP and NIMP.
The ki is determined by the binding affinity of the compound, defined as KA, and the rate
of phosphorylation, defined by kp. The best inhibitory rate is therefore defined by a
strong KA value and a fast kp rate (Coban, Carr et al. 2016).
In the inhibition experiments, the significant data for rat blood AChE sources had
faster rates of inhibition (ki) and therefore were more sensitive to inhibition by NEMP
and NIMP compared to their corresponding human samples. OP experiments with
paraoxon-inhibited rat and human plasma BChE also demonstrated the greater sensitivity
of rats versus humans (Ecobichon and Comeau 1973). The current data demonstrated
differences in BChE specimens of rats versus humans, but they were not statistically
significant.
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Considering the significant data, the more sensitive rat AChE and BChE were
also supported with stronger enzyme affinity, KA, as data demonstrated higher values
compared to the corresponding human KA values. Faster kp values were seen for the
human blood data versus the corresponding rat blood data, but the differences were
insignificant. The discrepancy in kp has been shown by researchers to be a result of the
lesser role of phosphorylation versus binding affinity, where correlation with ki is much
stronger with the binding affinity KA (Coban, Carr et al. 2016). In this experiment, the
lack of significance may indicate such a case where kp values have a lesser effect on the
ki value versus the KA.
A direct comparison between NEMP and NIMP inhibition potency can also be
made with the inhibition kinetics data. Researchers have demonstrated with human
erythrocyte AChE that inhibition rates for VX are greater than for sarin, making the
former a more potent inhibitor (Worek, Thiermann et al. 2004, Coban, Carr et al. 2016).
This was also observed in the data with significant comparisons, NEMP demonstrated
greater inhibitory rates compared to NIMP for rat and human erythrocyte AChE and rat
brain and skeletal muscle AChE. Literature on rat plasma AChE and BChE inhibition
kinetics was not available. As previously mentioned, the absence of significance for
some of the specimen sources may be a result of the variability in AChE and BChE
enzyme isomer types and concentrations present in the specimen sources (Lenz and
Maxwell 1981, Chatonnet and Lockridge 1989).
The active site of AChE and BChE is highly conserved genetically between
species, but the size of the active site gorge can vary considerably and may also play a
role in AChE and BChE differences as mentioned previously (Chatonnet and Lockridge
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1989, Masson and Lockridge 2010). Four polymorphisms of AChE have been identified
with only two being of clinical significance and may also account for differences (Hasin,
Avidan et al. 2005). One polymorphism is a glucocorticoid response element that is
related to increased OP sensitivity and the other is Asn substitution of His322 that is
responsible in blood typing and donor matching (Bartels, Zelinski et al. 1993, Ehrlich,
Ginzberg et al. 1994). BChE polymorphisms have also been identified and could explain
species differences as well (Primo-Parmo, Bartels et al. 1996, Souza, Mikami et al.
2005).
The chemical structure of the inhibitors can also influence the inhibition kinetic
values as demonstrated by many researchers (Worek, Thiermann et al. 2004). Research
has confirmed that small changes to alkyl residues on OPs and stereoisomers of OPs can
have substantial effects on ki (Worek, Thiermann et al. 2004). The alterations of the
nerve agent surrogates to make them less potent than the original agent could account for
some of the differences seen in the data.
Oxime Reactivation Kinetics of Surrogate Inhibited AChE and BChE: The
reactivation data provided important information about differences between oxime
reactivation of inhibited rat and human blood AChE and BChE. The data also defined
differences between NEMP and NIMP. In addition, the data provided informative insight
into which of the novel oximes were most effective against nerve agent surrogate
inhibited AChE and BChE.
In terms of comparing rat and human reactivation of NEMP and NIMP inhibited
AChE and BChE, there were only a couple differences. NEMP inhibited human plasma
AChE had significant differences in reactivation rates for 2-PAM and oxime 44.08 when
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compared to the corresponding rat plasma AChE. All other direct comparisons did not
indicate significant differences.
Interesting observations were also seen between the current research data and the
literature. Researchers have demonstrated sarin-inhibited human erythrocyte AChE had
greater 2-PAM reactivation rates versus VX, while sarin and VX-inhibited rat erythrocyte
AChE had similar 2-PAM reactivation rates (Worek, Reiter et al. 2002). The current
research data demonstrated that 2-PAM had greater reactivation rates for NEMP (the VX
surrogate) versus NIMP (the sarin surrogate). The novel oximes 44.08 and 44.25 had
opposite results with NIMP having greater reactivation rates than NEMP. Published rat
brain and skeletal muscle data were not available, but the current experiments
demonstrated NEMP inhibited rat brain AChE had reactivation rates that were greater
than NIMP for all the oximes. Rat skeletal muscle AChE had opposite results with NIMP
demonstrating greater reactivation rates compared to NEMP for all the oximes. Noting
differences in reactivation rates between rat skeletal muscle and brain towards NEMP and
NIMP would be important when considering effects seen in the rat model.
The same researchers have also observed VX-inhibited human erythrocyte AChE
had greater 2-PAM reactivation rates versus their corresponding rat specimens, while
sarin-inhibited rat erythrocyte AChE had greater 2-PAM reactivation rates versus their
corresponding human specimens (Worek, Reiter et al. 2002). The current research
demonstrates for NEMP inhibited human plasma AChE that 2-PAM and oxime 44.08
have significantly greater reactivation rates versus corresponding rat plasma AChE. All
other blood samples did not indicate significant differences between rat and human
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samples. This observation means that the rat reactivation data could be more
conservative versus a human model, so less oxime may be required for humans.
Researchers have also demonstrated that OP reactivation rates for rat brain AChE
is lower versus human erythrocyte AChE at lower concentrations (Lugokenski, Gubert et
al. 2012). This was not the case in the current experiment, but various concentrations of
inhibitor were not tested. In addition, direct comparison of blood and brain AChE can be
questionable due to the variations in tissue components and therefore was not analyzed
statistically for the current analysis.
Differences between the current results and the published literature may be due to
the, previously mentioned, variations of binding affinity seen with the different
compositions of AChE and BChE observed with the plasma and membrane bound
enzymes (Juul 1968, Dave, Syal et al. 2000). The affinity of AChE or BChE could
translate to variations in susceptibility to inhibition as suggested by some researchers
performing rat brain soman-inhibited AChE experiments on isoenzymes (Lenz and
Maxwell 1981). This could explain the differences seen between membrane bound
versus plasma solubilized enzyme in the current experiments as well. In addition, the
chemical structure of the oxime and the interaction with the phosphylated enzyme plays a
major role in the observed differences seen. The individual isoenzymes would need to be
explored to pinpoint actual effects on oxime reactivation and the other kinetic values.
The data also demonstrated where Oxime 44.08 and Oxime 44.25 fit in terms of
reactivation rates versus the most commonly used oxime antidote, 2-PAM, as the
reference. The current data in conjunction with data from other researchers also helped
predict overall rankings among the most common oximes used throughout the world. In
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terms of the specific oxime reactivation only 3 out of the 16 available blood and brain
and skeletal muscle sources indicated significant differences between the various oximes.
These 3 enzyme sources (NIMP inhibited human erythrocyte AChE and NIMP and
NEMP inhibited rat brain AChE) demonstrated that 2-PAM had significantly greater
reactivation rates compared to oxime 44.08 and oxime 44.25. In addition, the overall
blood data demonstrated 2-PAM had significantly greater reactivation rates versus oxime
44.08 and 44.25. Current literature demonstrates the best oxime for sarin and VXinhibited erythrocyte AChE reactivation is obidoxime, followed by HLö 7, then HI 6, and
lastly 2-PAM (Worek, Reiter et al. 2002). The obidoxime reactivation rate is around 4
times greater than 2-PAM, while HI 6 is slightly better than 2-PAM. This places oxime
44.08 and oxime 44.25 behind 2-PAM when considering the overall ranking of the
oximes. When comparing oxime 44.08 and 44.25 there are no significant data to
distinguish the two oximes, so the oximes are probably similar. The variability of
reactivation by different oximes has been explored previously by many researchers
(Worek, Thiermann et al. 2004). Further exploration into the acidity of the oximes, the
position of the oxime group on the pyridinium ring, and the orientation of the oxime
could help further define the effectiveness of the novel oximes for reactivation of
organophosphate-inhibited enzymes (de Jong, Verhagen et al. 1989, Worek, Thiermann
et al. 2004).
Aging and spontaneous reactivation of AChE and BChE: In this experimental
design, the spontaneous reactivation and aging rates provided a point of reference for
possible effects on inhibition and reactivation rates. In this case the effect was negligible,
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but a few observations confirmed findings of other researchers in regards to OP and
AChE or BChE interactions.
The longer aging of sarin was also observed in the clinical treatment records of
the Tokyo subway casualties where many of the exposed had fully recoverable AChE
(Yanagisawa, Morita et al. 2006, Masson and Lockridge 2010). Researchers have also
shown that aging of VX-inhibited human AChE and BChE can be restored to 70%
activity after 48 hours with 2-PAM treatment (Li, Schopfer et al. 2007). The same
research has also demonstrated negligible aging of VX-inhibited human BChE after 28
hours. Researchers performing kinetic analysis on rat and human blood with
methamidophos-inhibited AChE ghost and plasma BChE observed insignificant
spontaneous reactivation, supporting the findings of this study (Lugokenski, Gubert et al.
2012). Research on cyclosarin-inhibited human erythrocyte AChE and plasma BChE,
demonstrated that BChE aged at a faster rate than AChE (Worek, Eyer et al. 1998). This
was also observed in the data for NIMP and NEMP inhibited human erythrocyte AChE
and plasma AChE and BChE, where the BChE aging was at a higher rate but the
difference was not significant. The opposite was observed with the corresponding rat
specimens, but the differences were also not significant. The overall observations would
be important when considering rat and human models and looking at extended exposures
where spontaneous reactivation and aging are measurable for most OP exposures except
for soman which ages quickly with AChE and BChE inhibition (Carletti, Li et al. 2008,
Carletti, Aurbek et al. 2009, Carletti, Colletier et al. 2010).
In the experiment from the literature, the aging and spontaneous reaction was
observed over many hours, so the significance of the current data could be associated to
79

the hour time frame of the testing. This hour time frame is suitable for all kinetic rate
determinations except for spontaneous reactivation and aging which is best seen when
tested periodically over 20 to 48 hours on average (Carr and Chambers 1996, Worek,
Eyer et al. 1998, Li, Schopfer et al. 2007). Extending the time frame for aging and
spontaneous reactivation could make the observed differences more statistically
significant.
Conclusion
In general, nearly all IC50 concentrations of NIMP were higher than NEMP. In
addition, human IC50 values were greater than corresponding rat IC 50 values. This
indicates rat samples may be more sensitive to NEMP and NIMP versus humans which
suggests that the rat information may be conservative for human predictions. Together
these are important observations when considering nerve agent surrogate dosing in the
laboratory rat model and expectations in human exposures. The ki values in rats were
overall greater than humans for this experiment which supports published materials
(Coban, Carr et al. 2016). The overall reactivation data suggests that 2-PAM is a
significantly greater reactivator for NEMP and NIMP compared to the novel oximes, but
the combined rat and human reactivation data only demonstrated 3 out of 16 specimen
types where the oximes were significantly different from each other. This suggests the
novel oximes may be comparable to 2-PAM in potential efficacy. In addition,
reactivation rate differences between the species for the various oximes were
significantly different for NEMP inhibited plasma AChE. In the cases where the species
did have significant differences, the humans had greater reactivation rates compared to
rats. This indicates that rats may be more conservative to reactivation by the oximes
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versus humans, so human dosages would need to be less. Spontaneous reactivation and
aging rates were negligible, but correlated with findings of published research (Li,
Schopfer et al. 2007, Lugokenski, Gubert et al. 2012). What could account for the
observed differences? Researchers suggest isoenzyme variations between rat and human
AChE and BChE could play a role, and AChE and BChE active site gorge size
differences could also account for variations, and oxime chemical structure can make a
difference (Juul 1968, Dave, Syal et al. 2000, Worek, Thiermann et al. 2004, Masson and
Lockridge 2010). In summary, the humans may require more nerve agent surrogate to
experience the same inhibition as rats. Also when administering novel oximes, the faster
human reactivation rates may indicate less oxime is required versus rats. The overall data
provide important information for extrapolating what to expect in human models when
obtaining rat model experimental results for the novel oximes and nerve agent surrogates
tested. The next step would be to create a pharmacokinetic model using the kinetic
values.
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CHAPTER IV
PHARMACOKINETIC MODEL
Introduction
The field of pharmacokinetics studies the chemical and metabolite distribution
over time in the body of a living organism (Mosby Inc. 2013). Many researchers of
organophosphates (OPs) utilize pharmacokinetic modelling to predict how specific OP
exposures will affect the body in certain scenarios. They explore OP pesticide exposures,
nerve agent exposures, and antidote effectiveness (Gearhart, Jepson et al. 1990, Worek,
Szinicz et al. 2005). Due to the ethical limitations of testing OPs in humans and species
differences when using animal models, pharmacokinetic models play an important role in
extrapolating animal studies into reasonable human predictions (Dawson 1994, Worek,
Reiter et al. 2002, Worek, Szinicz et al. 2005).
The development of pharmacokinetic models for OP exposures takes advantage of
multiple data sets from research with different animal species and human blood AChE
and BChE substrate kinetics, real nerve agent inhibition kinetics, commercial and novel
oxime antidotes reactivation kinetics, and aging and spontaneous reactivation kinetics
(Gearhart, Jepson et al. 1990, Worek, Reiter et al. 2002, Worek, Szinicz et al. 2005,
Sweeney, Langenberg et al. 2006).
Testing of nerve agent exposure and corresponding antidotes is primarily
accomplished economically via the Sprague Dawley-derived rat or similar rat models
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(Chambers, Chambers et al. 2013). Actual nerve agent testing on humans is limited to
blood components and utilizing in vitro assays (Worek, Mast et al. 1999, Worek,
Thiermann et al. 2004, Coban, Carr et al. 2016). To improve data extrapolation from rat
to humans a comparative kinetic analysis could go a long way in providing the initial
information for translating antidote dosing for humans and help develop dynamic models
proposed by previous researchers (Gearhart, Jepson et al. 1990, Worek, Szinicz et al.
2005). Pharmacokinetic modeling has long been used to determine estimated rates of
chemical and drug metabolism (Emond, Michalek et al. 2005). Researchers utilize
known human pharmacokinetic and known animal toxicokinetic data to extrapolate the
necessary information that they need. Many of these kinetic rates have been determined
in the literature for real nerve agents and commercial oxime antidotes, but these rates
have not been determined for the nerve agent surrogates and novel oximes used in this
laboratory (Worek, Szinicz et al. 2005). Following the dynamic model developed by
Worek et al. from 2005, a dynamic pharmacokinetic model is presented here using the
current human kinetic data and rat kinetic data from experiments with nerve agent
surrogates and novel oximes described in Chapter 3. The proposed model provides the
first step towards developing a human pharmacokinetic model for the novel oximes and
nerve agent surrogates.
The Worek dynamic model utilized published human pharmacokinetic data for 2PAM, which provided critical information on absorbance and excretion rates for 2-PAM.
The researchers also utilized published human plasma acetylcholinesterase (AChE)
kinetic data for establishing inhibition rates for real nerve agents and reactivation rates
for 2-PAM. The researchers utilized published guinea pig toxicokinetic data to determine
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lethal doses, and also to determine absorbance and excretion for actual nerve agents. To
test the dynamic model, the researchers utilized published human case study data from
real world OP exposures to test the predictive capability of the model. The Worek group
only tested intravenous and percutaneous OP exposure routes. The dynamic
pharmacokinetic model proposed here follows the earlier model developed by Worek et
al. from 2005, but also proposes an additional respiratory exposure route developed by
Spruit et al. (Spruit, Langenberg et al. 2000). The current proposed model utilized human
and rat kinetic values established with our nerve agent surrogates and novel oximes from
Chapter 3. The guinea pig toxicokinetic data used by Worek will be replaced with rat
toxicokinetic data that has yet to be accomplished for the nerve agent surrogates in future
experiments. All graphical depictions below are hypothesized human results based on
the 2-PAM data used in Worek’s dynamic model and the kinetic similarities seen with the
oximes and 2-PAM from Chapter 3. Data charts below are from the published literature
when indicated or from the kinetic work from Chapter 3.
Materials and Methods
Model development
The proposed model was based on previous work done by Worek et al. and their
dynamic model from 2005 (Worek, Thiermann et al. 2004, Worek, Szinicz et al. 2005).
The premise behind a dynamic model requires the creation of equations that take into
account the inhibition of AChE or BChE, the reactivation of the inhibited enzymes via
oximes, and natural mechanisms of aging and spontaneous reactivation. All of these
parameters can be described by kinetic rate constants which have been determined
previously. The rate constants can then be expressed in differential equations for input
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into a proposed model. Figure 8 below displays the breakdown of the standard kinetic
equation into separate components and then subsequent equations for the
pharmacokinetic model. All equations in Figure 8, except for Equation 13, were slightly
modified from Worek’s original equations from 2005 and assume that the forward
reaction is primarily occurring.
The list of equations below describe: (13) Standard overall equation describing
AChE or BChE inhibition, phosphorylation, reactivation, and aging. Brackets depict
concentration, [E] is enzyme, [I] is enzyme inhibitor, [OX] is oxime reactivator, [EI] is
enzyme inhibitor complex, [EI]R is reversible enzyme inhibitor complex, [EI]I is inhibited
enzyme inhibitor complex, [EI]a is aged enzyme inhibitor complex, [EIOX] is enzyme
inhibitor oxime complex. Equations (14), (15), (16), and (17) describe the separate
equations for the necessary kinetic reactions that play roles in calculating an overall
dynamic model. Equation (18) describes the combined dynamic model equation with all
the necessary kinetic parameters included. [OXI] is the oxime inhibitor complex. [EP] is
the enzyme product complex. The rate constants are similar to previous Chapter
descriptions. The kobs is the same as kapp.
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𝑘𝑟
𝑘1
𝑘𝑝
→
[𝐸] + [𝐼] ↔ [𝐸𝐼]𝑅 → [𝐸𝐼]𝐼
→
𝑘𝑎
𝑘−1

Overall Equation

[𝐸] + [𝑂𝑋𝐼]
[𝐸𝐼]𝑎

𝑘𝑖

Inhibition Equation

[𝐸] + [𝐼] ↔ [𝐸𝐼]𝑅
−

(13)

(14)

𝑑𝐸 𝑑(𝐸𝐼)
=
= 𝑘𝑖 ∗ [𝐸] ∗ [𝐸𝐼]
𝑑𝑡
𝑑𝑡

𝐾

𝑘

Reactivation Equation [𝐸𝐼] + [𝑂𝑋] ↔𝐷 [𝐸𝐼𝑂𝑋] →𝑟 [𝐸] + [𝑂𝑋𝐼]

(15)

𝑑[𝐸]
= 𝑘𝑜𝑏𝑠 ∗ [𝐸𝐼 + 𝐸𝐼𝑂𝑋]
𝑑𝑡
𝑘𝑜𝑏𝑠 =

𝑘𝑟 ∗ [𝑂𝑋]
𝐾𝐷+[𝑂𝑋]

= 𝑘𝑠 ∗ [𝐸𝐼]

(16)

= 𝑘𝑎 ∗ [𝐸𝐼]

(17)

= −𝑘𝑖 ∗ [𝑂𝑋𝐼] ∗ [𝐸] + 𝑘𝑠 ∗ [𝐸𝐼] + 𝑘𝑜𝑏𝑠 ∗ [𝐸𝐼 + 𝐸𝐼𝑂𝑋]

(18)

Spontaneous Reactivation

𝑑[𝐸]
𝑑𝑡

Equation

Aging Equation

𝑑[𝐸𝐴]
𝑑𝑡

Combined Dynamic Equation
𝑑[𝐸]
𝑑𝑡

𝑑[𝐸𝑃]
= −𝑘𝑖 ∗ [𝑂𝑋𝐼] ∗ [𝐸] − 𝑘𝑠 ∗ [𝐸𝐼] − 𝑘𝑜𝑏𝑠 ∗ [𝐸𝐼 + 𝐸𝐼𝑂𝑋] − 𝑘𝑎 ∗ [𝐸𝑃]
𝑑𝑡
Figure 8

List of equations
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Equation 16 is the raw equation used by researchers to demonstrate dynamic
changes of AChE or BChE activity while accounting for enzyme kinetics, inhibitor
toxicokinetics, and oxime pharmacokinetics (Worek, Szinicz et al. 2005). A dynamic
pharmacokinetic model is proposed utilizing these calculations along with the previously
generated data on human blood AChE and BChE kinetics, nerve agent surrogate’s
inhibition kinetics for nitrophenyl ethyl methylphosphonate (NEMP for VX) and
nitrophenyl isopropyl methylphosphonate (NIMP for sarin), and novel oxime reactivation
kinetics for oxime 44.08 and 44.25.
The time course for the oxime concentrations will be calculated using a Bateman
function equation described below as Equation 19 (Bateman 1931, Worek, Szinicz et al.
2005). [OX] is the oxime concentration, Dose is oxime dose from start, VDSS is volume
of distribution, kabs is rate constant of absorption, kel is rate constant of excretion, t is
time, and e is an exponential function.

[𝑂𝑋] =

𝐷𝑜𝑠𝑒
𝑉𝐷𝑠𝑠

∗

𝑘𝑎𝑏𝑠
𝑘𝑎𝑏𝑠 −𝑘𝑒𝑙

∗ (𝑒 −𝑘𝑒𝑙∗𝑡 − 𝑒 −𝑘𝑎𝑏𝑠 ∗𝑡 )

(19)

The time course for the NEMP and NIMP inhibitor concentrations will need to be
determined with a multi-exponential function similar to the equations described by the
Worek group for intravenous (IV) and percutaneous exposure, but for the proposed
model a respiratory, intravenous, and percutaneous exposure to NEMP and NIMP will be
considered as well (Spruit, Langenberg et al. 2000, van der Schans, Lander et al. 2003,
Worek, Szinicz et al. 2005). Equations 20, 21, and 24 below are from Worek’s 2005
work with VX and sarin. Equations 22 and 23 below are from Spruit’s 2000 work with
92

sarin. These equations will be used to determine rat toxicokinetic data and along with
human pharmacokinetic data a prediction of human plasma NEMP or NIMP
concentrations will be made with the overall dynamic model described earlier. For the
equations below, brackets represent final concentration of inhibitor, and A, B, C, D
represent doses of NIMP or NEMP and a, b, c, d represent rate constants, and e is an
exponential function, and t is time. The multiple concentrations of inhibitor (A, B, C, D)
and their corresponding rates (a, b, c, d) provide a means for determining the best
exponential equation for specific exposure types. Based on research by Van der Shans et
al. a bi- or tri-exponential equation can be used to improve data accuracy for each model
described below based on the type of exposure (van der Schans, Lander et al. 2003).
Researchers have confirmed through published research that the below exponential
equations are suitable for toxicokinetic determination for VX and sarin (Spruit,
Langenberg et al. 2000, Worek, Szinicz et al. 2005). Doses were adjusted from mg/kg to
molar units using the molecular weight of the compound being used and a standard
human weight of 70 kg (Spruit, Langenberg et al. 2000, Worek, Szinicz et al. 2005).
Since NEMP and NIMP have been proven to be effective surrogates for VX and sarin, it
is reasonable that the models below may be effective at determining rat toxicokinetics for
the overall predictive model. Adjustments can be made as necessary to the proposed
exponential models below to improve the toxicokinetic data.

IV NEMP Exposure

[𝐼] = 𝐴 ∗ 𝑒 −𝑎𝑡 + 𝐵 ∗ 𝑒 −𝑏𝑡

(20)

IV NIMP Exposure

[𝐼] = 𝐴 ∗ 𝑒 −𝑎𝑡 + 𝐵 ∗ 𝑒 −𝑏𝑡 + 𝐶 ∗ 𝑒 𝑐𝑡

(21)
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Respiratory NEMP/NIMP exposure
Absorption

[𝐼] = 𝐴 + 𝐵 ∗ 𝑒 −𝑏𝑡

(22)

Distribution

[𝐼] = 𝐶 ∗ 𝑒 −𝑎 + 𝐷 ∗ 𝑒 𝑑𝑡

(23)

Percutaneous NEMP/NIMP exposure
[𝐼] = [𝐼0 ]𝑒 −𝑒𝑡 − [𝐼]𝑒 −𝑎𝑡

(24)

Model Validation
The model validation would be done using data from published cases of OP
exposed and treated human patients. The same data used by Worek et al. from 2005 will
be used to test the proposed model. The data required would be the amount of OP
exposure, the results for periodic blood samples to determine OP and oxime levels, and
the AChE activity. Using the kinetic data for inhibition from Table 8 below, and the
reactivation rates from Table 9 below, and the concentrations of the OP (I in the
equation) and oxime (OX in the equation), the expected AChE activity can be calculated
and compared to the actual data. Equation 25 can be applied to determine the AChE
activity. KD is the oxime dissociation constant which must be determined for each oxime
and AChE and BChE source.

[𝐸]
[𝐸𝐼+𝐸𝐼𝑂𝑋]

=

𝑘𝑟
1+ 𝐾

𝑘𝑖 ∗[𝑂𝑋𝐼]∗( [𝑂𝑋]𝐷 )
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(25)

Table 8

Rate constants for inhibition

Rate constants for inhibition of AChE and BChE by OP (ki) and for aging (ka) and
spontaneous reactivation of OP inhibited AChE and BChE (ks). Data for human
erythrocyte AChE, pH 7.4, 37 oC, was obtained from Chapter 3.

Table 9

Rate constants for dissociation (KD) and reactivation (kr)

Rate constants for dissociation (KD) and reactivation (kr) for various oximes after NEMP
or NIMP inhibition of blood sources of AChE or BChE. Data for human erythrocyte
AChE, pH 7.4, 37 oC, was obtained from Chapter 3. ND = Not Done
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Calculations of enzyme activities
In experimental scenarios conducted by researchers, the real sarin nerve agent is
considered to have a short biological half-life and is tested via intravenous and
respiratory exposures (Spruit, Langenberg et al. 2000, Worek, Szinicz et al. 2005). Real
VX nerve agent is considered a persistent OP and would be tested via intravenous and
percutaneous exposure routes (van der Schans, Lander et al. 2003, Worek, Szinicz et al.
2005). The experimental model assumes a simultaneous intravascular or percutaneous
exposure to nerve agent and intramuscular administration of oxime. The oxime dosage
will be based on current dosing regimens for 2-PAM with 600-1800 mg (MW 172.6).
The dosing for oxime 44.08 (MW 400.88) and oxime 44.25 (MW 472.55) have yet to be
determined (Sidell, Takafuji et al. 1997, Worek, Szinicz et al. 2005, Chambers, Chambers
et al. 2013).
Known human pharmacokinetic data can be used to calculate 2-PAM
concentrations in plasma, but the same data for humans have not been determined yet for
the novel oximes 44.08 and 44.25. Rat model pharmacokinetic data can be used to
determine initial plasma concentration for the novel oximes. Actual toxicokinetic data
for human nerve agent exposure is not available because of ethical reasons. Guinea pig
data are commonly used for estimating human nerve agent exposure and calculating
plasma concentrations of nerve agent (Spruit, Langenberg et al. 2000, van der Schans,
Lander et al. 2003, Worek, Szinicz et al. 2005). Using rat models, NEMP and NIMP
toxicokinetic data can be generated for determining nerve agent surrogate concentrations
in plasma and have yet to be determined.
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The AChE IC50 for brain tissue is considered a great predictor for nerve agent
lethality (Fawcett, Aracava et al. 2009, Meek, Chambers et al. 2012). Based on research
conducted with IC50s for NEMP and NIMP for brain, the estimated LD50 can be
determined and used in the pharmacokinetic analyses. Since IC50s for NEMP and NIMP
were determined to be slightly higher than their corresponding real nerve agent, then the
LD50 may also be slightly higher as well (Meek, Chambers et al. 2012).
The proposed model will utilize intravenous and percutaneous nerve agent
surrogate exposure scenarios and calculations established by Worek, but will also utilize
the respiratory scenario and pertinent calculations set by Spruit (Spruit, Langenberg et al.
2000, Worek, Szinicz et al. 2005). In conjunction with rat toxicokinetic data and human
pharmacokinetic data the calculations will help predict the AChE and BChE activity for
each scenario.
Results
Following the findings of Worek’s 2005 research on kinetic-based dynamic
modeling and the data generated from kinetic analysis of 2-PAM, oximes 44.08 and
44.25, and NEMP and NIMP inhibition, some predictions can be made for the proposed
model (Worek, Szinicz et al. 2005). In Worek’s dynamic model it was demonstrated that
sarin-inhibited AChE, via intravenous (IV) injection, was easily restored after
simultaneous intramuscular (IM) oxime injection of 600 mg of 2-PAM. At high sarin
doses it was also demonstrated that AChE activity can be quickly restored. For the VX
testing the results were different. VX is described by the researchers as having a high
persistence and despite the maximum 2-PAM oxime dose, the AChE activity increased
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and then decreased over time. This is described as a result of quick oxime elimination
and continued VX inhibition (Worek, Szinicz et al. 2005).
Considering the published kinetic values for VX and sarin with subsequent
reactivation by 2-PAM, and the 2-PAM data obtained with NEMP and NIMP along with
the oximes, some reasonable conclusions can be made (Worek, Szinicz et al. 2005, Meek,
Chambers et al. 2012). Work described in Chapter 3 has demonstrated 2-PAM, oxime
44.08 and 44.25 have similar reactivation rates in a variety of rat and human AChE and
BChE sources inhibited by NEMP and NIMP. So some of the dynamic modeling data
from Worek’s 2005 paper for sarin and VX exposure and 2-PAM reactivation may be
similar for NEMP and NIMP exposure and subsequent oxime 44.08 and 44.25
reactivation. In Figures 3 to 6 below, hypothesized human data graphs are displayed
based on Worek’s 2005 data and the observations from published work of Meek and
Chambers (Worek, Szinicz et al. 2005, Meek, Chambers et al. 2012, Chambers,
Chambers et al. 2013). NEMP, NIMP, novel oxime pharmacokinetic and toxicokinetic
data have yet to be determined to compare against real VX and sarin in rat models.
Respiratory dynamic modeling was not determined by Worek et al. in 2005, but
Equations 22 and 23 above have been proposed using literature from Spruit et al. (Spruit,
Langenberg et al. 2000).
The information for Table 10 below is taken from Worek’s 2005 data for
calculated human plasma concentrations of 2-PAM after IM injection of 1 to 3
autoinjectors equivalent per 70 kg person (600mg, 1200 mg, and 1800 mg) (Worek,
Szinicz et al. 2005). The VDss value was normalized for a 70 kg body weight and the
oxime plasma concentrations were calculated with the Bateman Equation 19 described
98

above. The human experimental 2-PAM values from Table 10 for the different
parameters were obtained from the following as indicated: a(Sidell, Groff et al. 1972),
b

(Jovanovic 1989). Similar human pharmacokinetic data would need to be generated for

oxime 44.08 and 44.25 to determine the needed variables. The Figure 9 graphical
depiction below is hypothesized results for human plasma concentrations for oxime 44.08
and 44.25 except for the doses identifying the three curves has yet to be determined and
are identified generically as high, medium and low doses.
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Figure 9

Hypothesized human plasma oxime concentration data

The dose is based on average human weight of 70 kg.
Table 10

Oxime parameter data

Dose was transformed using the oxime molecular weight. TBD = to be determined
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The information for Table 11 below is taken from Worek’s 2005 data for
calculated human AChE activities after IV sarin injection followed simultaneously with
IM 2-PAM injection (Worek, Szinicz et al. 2005). The AChE activity changes were
calculated with published toxicokinetic guinea pig sarin data and pharmacokinetic human
2-PAM data (Spruit, Langenberg et al. 2000, Worek, Szinicz et al. 2005). Based on
published data on NIMP and the novel oximes from Meek et al from 2012 and Chambers
et al. from 2013 and the sarin and 2-PAM data from Worek’s 2005 paper, the
hypothesized human plasma AChE activity depicted in Figure 10 was generated below.
Equation 20 previously displayed above [sarin/NIMP] = A x eat + B x ebt allows the
determination of human sarin serum concentrations from the guinea pig toxicokinetic
data and human 2-PAM pharmacokinetic data (Spruit, Langenberg et al. 2000). The
results for NIMP and oxime 44.08 and 44.25 could be similar to the information depicted
here when conducted via rat experiments for the toxicokinetics and human experiments
for the pharmacokinetics.
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Figure 10

Hypothesized NIMP human IM exposure data

Table 11

Animal LD50 data

TBD = to be determined
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The information for Table 12 below is taken from Worek’s 2005 data for
calculated human AChE activities after IV VX injection followed simultaneously with
IM 2-PAM injection at 600 mg and 1800 mg (Worek, Szinicz et al. 2005). NEMP and
Oxime 44.08 and 44.25 would be injected similar to VX and 2-PAM, but dosage levels
still have to be determined. VX guinea pig exposure was at 1, 3, and 5 x LD50 and
provided measurable plasma concentrations for reference. NEMP rat data would need to
be determined to provide corresponding LD50 information. The VX animal
concentrations along with human pharmacokinetic data for the oximes were used to
calculate the corresponding human VX plasma concentrations listed below in the table.
Equation 21 above, a three-exponential equation for VX concentration A x eat + B x ebt +
C x ect was used to determine the human values below in Table 12 (van der Schans,
Lander et al. 2003). A linear relationship was expected with A, B, and C for guinea pig
VX dosing and for the elimination constants a, b, and c, the mean values were used (van
der Schans, Lander et al. 2003). Similar protocol for VX will be used for NEMP, but rat
NEMP data still needs to be generated and could be used in place of the guinea pig data
for generating the corresponding human data. Figure 11 below is a graphical depiction of
what human AChE activity levels may look like for various NEMP LD50s.
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Figure 11

Hypothesized NEMP human IM exposure data

Table 12

Calculated human from animal data

TBD = to be determined
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The information for Table 13 below is taken from Worek’s 2005 data for
calculated human AChE activities after percutaneous VX exposure followed
simultaneously with IM 2-PAM injection. The guinea pig information provided VX
toxicokinetics and the human 2-PAM data provided pharmacokinetics to determine the
necessary information below (Worek, Szinicz et al. 2005). Oxime 44.08 and 44.25 would
be injected similar to 2-PAM, but dosage levels still have to be determined. VX guinea
pig exposure at 1, 3, and 5 x LD50, would have to be done for rats exposed to NEMP, so
the human plasma AChE activity could be determined as hypothesized in the graphical
depiction below in Figure 12. The VX animal concentrations along with human
pharmacokinetic data for 2-PAM were used by Worek to calculate the VX human LD50
estimates in the table below (Worek, Szinicz et al. 2005). Equation 24 from above, [VX]
= [VX0] x eel*t – [VX0] x eabs*t was used to determine the human values below (van der
Schans, Lander et al. 2003). Human VX concentrations were determined assuming linear
dose relationship for VX (van der Schans, Lander et al. 2003). Similar protocol for VX
will be used for NEMP, but rat NEMP dosing concentrations still need to be determined.

105

Figure 12

Hypothesized human percutaneous exposure data

Table 13

Human estimates using dynamic model

TBD = to be determined
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Discussion and Conclusion
Research from Worek et al. have demonstrated the validity of the dynamic model
for reactivating sarin and VX inhibited AChE using 2-PAM (Worek, Szinicz et al. 2005).
Considering the recent comparison between 2-PAM and oximes 44.08 and 44.25 seen in
Chapter 3, it is expected that the oximes will perform similar to 2-PAM in the dynamic
modeling. As demonstrated above, critical rat and human data have yet to be determined
that could provide a better prediction for the novel oximes and nerve agent surrogates
performance in a calculated human model. LD50 values in rats would be critical to
predict the nerve agent surrogates’ abilities to inhibit in the human model. In addition,
the novel oxime dosing in the human model is also an important parameter that needs to
be determined for the dynamic model to be a better predictor. Another factor to consider
is the greater lipophilicity of the novel oximes compared to 2-PAM which could play a
role in overall absorption, distribution, and excretion. The increased lipophilicity could
cause distribution into lipophilic cellular material and require increased doses compared
to 2-PAM. Once all these parameters have been determined and explored, the model
testing for the surrogates and novel oximes can be accomplished using the same case
study data used by Worek et al. in 2005 (Sidell, Takafuji et al. 1997, Spruit, Langenberg
et al. 2000, Worek, Szinicz et al. 2005). The proposed model will help lead the way with
the optimization of treatment protocols for NIMP and NEMP exposed rats and
subsequent optimization of protocols for treating humans with our novel oximes.
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CHAPTER V
CONCLUSION
The risk of exposure to OPs as pesticides and nerve agents continues to be a
problem throughout the world. Though current antidotes do provide reactivation for the
peripheral nervous system, there has yet to be discovered a viable antidote to effectively
reactivate AChE in the central nervous system. The results of our research have provided
additional support for the efficacy of newly developed oximes that can penetrate the
blood brain barrier and reactivate the central nervous system.
The cyclosarin surrogate, NCMP, has proven to be a formidable agent for
inhibiting AChE, similar to the real nerve agent cyclosarin. The inability of the novel
oximes to generate appreciable reactivation is similar to 2-PAM. Despite this finding,
preliminary data for combined antidote testing did demonstrate an interesting increase in
rat brain reactivation in vitro when simultaneously incubated with NCMP, 2-PAM, and
novel oxime 46.43 or 46.49. Exploring the interaction within the testing system between
the NCMP, 2-PAM, and novel oximes could provide critical insight into the mechanisms
occurring. Discoveries at the molecular level could provide information for further
refinement of the oximes for reactivating NCMP more effectively.
Kinetic analyses provide a quantitative means to evaluate the effects of inhibitors
and reactivators on different enzymes. In addition, kinetic analyses can also provide a
means to quantitate differences between the same enzyme in different species. In the
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current research the kinetic analysis of rat and human erythrocyte acetylcholinesterase
(AChE) and plasma AChE and butyrylcholinesterase (BChE) and rat brain and skeletal
muscle AChE provided important kinetic data for making critical comparisons. The
current research confirmed the potency differences between the VX nerve agent
surrogate, NEMP, and the sarin surrogate, NIMP, where NEMP was more potent for both
humans and rats. In addition, differences between human and rat blood AChE and BChE
inhibition by the surrogates demonstrated the increased sensitivity of the rat enzymes.
Finally, the overall oxime reactivation data suggests 2-PAM is a greater reactivator
compared to oxime 44.08 and 44.25, but the close proximity of the rates suggests they are
still comparable.
The necessary deficiency in nerve agent research is the inability of in vivo human
testing due to ethical limitations. Researchers are therefore limited to using
pharmacokinetic data from humans and toxicokinetic data from animal models. The
current research has not reached the stage of toxicokinetic animal testing of the nerve
agent surrogates or real nerve agent with subsequent use of the novel oximes. In
addition, the novel oximes have not yet reached the stage for generating human
pharmacokinetic data. Despite the lack of some data, a dynamic pharmacokinetic model
was proposed using the kinetic values from the rat and human blood experiments
described here and available published human data. Proposed calculations, data tables,
and graphs were generated to provide the initial step towards a rat-based dynamic
pharmacokinetic model for predicting human results and improving rat model testing of
the nerve agent surrogates and novel oximes.
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The future direction of this research could include further exploration of NCMP
and the interaction it had with 2-PAM and oximes 46.43 and 46.49. This could be done
via amino acid substitutions on acetylcholinesterase and determining sites on the enzyme
that are interacting with the NCMP or oximes. The results could help pinpoint ways the
oximes could be improved. Another future direction for the research could be to continue
acquiring the necessary rat OP toxicokinetic and human oxime pharmacokinetic data
needed to implement the proposed rat-based dynamic pharmacokinetic model.
Completing the model will help with the development of optimized treatment protocols
for the nerve agent surrogate exposed rats and subsequently help project protocols for
human treatment using the novel oximes. Together the research further validates the
effectiveness of the nerve agent surrogates for evaluating the novel oximes and also
strengthens the novel oximes use as an improved nerve agent antidote
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EXPERIMENTAL PROTOCOLS
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Blood AChE and BChE Preparation Procedure
Sources of AChE in human and rat blood are found on the erythrocyte outer
membrane and also in the plasma. The source of BChE in human and rat blood is
primarily suspended in the plasma. The preparation of human and rat erythrocyte ghost
and separation of the plasma was accomplished with modified procedures from Dodge et
al. and Worek et al. The pools of erythrocyte ghost or plasma were created with at least
five different specimens from rats or human sources. For erythrocyte ghost preparation,
blood was collected in vacutainers containing EDTA anticoagulant and kept on ice
throughout the processing. The amount of blood in each container was approximately
recorded. This value was used to return the erythrocyte ghost back to the original volume
at the end of the procedure. Blood containers were spun at 3000xg for 10 minutes at 4 oC
(Eppendorf Centrifuge 5702R, A-4-38 rotor). After centrifugation the specimen tubes
should have a layer of erythrocytes at the bottom and a layer of plasma at the top. The
top plasma layer was removed from each blood container and pooled into a single glass
test tube. The amount of plasma removed was recorded for each blood container and this
volume removed was used to determine the amount of SPB used for the erythrocyte
washing steps. The removed pooled plasma was allocated into 1 ml conical tubes with
250 μl of plasma in each tube and frozen at -80 oC until testing. The remaining
erythrocytes were washed with 2 times the plasma volume removed from each sample.
All washes and dilutions were accomplished with SPB (0.1 M, pH 7.4). The samples
were washed 3 times by spinning at low speed for 1000xg for 10 minutes at 4 oC,
supernatant was discarded and SPB was added and mixed, then the cycle repeated
(Eppendorf Centrifuge 5702R, A-4-38 rotor). After the final wash, the packed
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erythrocytes were diluted with hypotonic phosphate buffer by 20 times the volume of
plasma originally removed from each tube. The diluted samples were mixed and cells
allowed to lyse for 10 minutes. The lysed mixtures were centrifuged at 50,000xg for 30
minutes at 4 oC (Beckman Coulter Avanti Centrifuge, JA-20 rotor). The supernatant was
removed, samples were pooled, and the erythrocytes were diluted to the original sample
volume from the original specimens. To remove excess hemoglobin, the samples were
washed 1 time by spinning at low speed for 5000xg for 5 minutes at 4 oC, supernatant
was discarded and SPB (0.1 M, pH 7.4) was added to the original sample volume
(Eppendorf Centrifuge 5415C, F-45-18-11 rotor). A 15 ml glass Pyrex homogenizer was
used to thoroughly mix samples and then aliquot 250 μl into conical tubes and store at 80 oC. To ensure optimal testing, pooled samples were analyzed to obtain baseline
activity and testing protocol parameters were adjusted accordingly.
Rat Solid Tissue AChE Preparation Procedure
Rat cerebral cortex and medulla oblongata and skeletal muscle was ground with a
Polytron PT 10-35 Grinder and then homogenized with a Heidolph Homogenizer and a
Teflon pestle in cold Tris-HCl buffer (0.05 M, pH 7.4) at a concentration of 40 mg/ml for
brain or 100 mg/ml for skeletal muscle. The homogenate was filtered through glass wool
or gauze. Five different rat samples were utilized per pooled sample. Samples were
aliquoted into 4 ml glass vials and maintained at -80 oC until testing.
AChE and BChE Substrate Kinetics Procedure
For each pool of samples, a minimum of one 96-well microtiter plate was used.
The protocol for AChE and BChE testing was adapted from a modified Ellman’s AChE
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activity test. For each pool of samples, a minimum of one 96-well microtiter plate was
used and three different pools were run for each experiment and the average was
calculated along with the standard error. Ghost AChE or plasma AChE or BChE samples
were thawed and kept on ice until testing. Plasma and ghost specimens were diluted with
SPB (0.1M, pH 7.4) appropriately to ensure approximately 0.3 absorbance units of
activity. Ghost AChE was thoroughly homogenized using a glass Tenbroek mortar and
pestle and hemoglobin removed via centrifugation and removal of supernatant at 5000xg
for 5 minutes at 4 C (Eppendorf Centrifuge 5415C, F-45-18-11 rotor). To prevent
decreases in enzyme activity washing was minimized. One 96-well plate was used to
carry out the substrate kinetics. Each experimental parameter and control was carried out
in triplicate. 250 μl of specimen was loaded in each testing well with 300 μl as the final
testing volume. Eserine sulfate at FC 10-5 M was added to negate any cholinesterase
activity in one control column. Ethanol with FC of 2% was added to demonstrate
maximum activity in one control column. A blank well without substrate and just DTNB
and SPB was utilized to demonstrate background absorbance. The following 8 well
columns were set up for the various concentrations of substrate to be added right before
reading the plate on the spectrophotometer. DTNB was added to all wells at a FC 0.002
M. The loaded plate was placed in a Jitterbug plate warmer at 37 C for 15 minutes at a
level 3 shake. A single row on a separate plate was prepared to hold the necessary
substrate mixtures (160 μl per well) to be added to the experimental plate prior to testing
on the plate reader. The eserine and ethanol wells (columns 1 and 3) received ATCh or
BTCh at FC 0.02 mM. The blank wells (columns 2 and 4) received ethanol with FC of
2% and no substrate was added to these wells. The subsequent wells (columns 5 to 12)
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received diluted ATCh or BTCh substrate solutions that provided final concentrations
ranging from 0.02 mM through 2.5 mM. Substrate mixtures were kept on ice and
covered with tape prior to testing. After incubation and mixing, the loaded testing plate
was placed on the plate reader for analysis and a multi-channel pipette was used to
dispense the various ATCh or BTCh mixtures or ethanol as necessary and the
spectrophotometer was started. Table 14 below depicts plate setup for substrate kinetics.
The procedure for rat solid tissue was similar to the above protocol for blood with
the following exceptions. Pooled homogenate was thawed and mixed using a glass
Tenbroek mortar and pestle and then centrifuged at 5000 RCF for 5 minutes at 4 C to
remove excess cellular debris in the supernatant (Eppendorf Centrifuge 5415C, F-45-1811 rotor). The intact pellet was returned to the same sample volume with fresh Tris
buffer (0.05 M, pH 7.4) and mixed thoroughly. Each experimental parameter and control
was carried out in triplicate, but 150 μl of specimen was loaded instead of 250 μl as
previously performed for blood specimens. The final concentration of each tissue was 1
mg equivalent/ml per well with a final well-volume of 200 μl. Tris buffer was used to
dilute specimens or perform any other action needing buffer for rat solid tissue.
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Table 14

Plate schematic for substrate kinetics

Calculation: For each concentration and control, the velocity was calculated.
The velocities were then used to formulate a Lineweaver Burk plot with the reciprocal of
each velocity on the y-axis and the reciprocal of each ATCh (BTCh) concentration on the
x-axis. The resulting data were used to formulate a linear line with a squared correlation
coefficient (R2-value) greater than 0.9 for acceptable results. The Kmapp = -slope and Vmax
= x-intercept.
AChE and BChE Inhibition Kinetics Procedure
The protocol for AChE and BChE inhibition testing was adapted from a modified
Ellman’s AChE activity test using a 96-well plate. For each pool of samples, a minimum
of four 96-well microtiter plates were used and three different pools were run for each
experiment and the average was calculated along with the standard error. Reading times
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for the inhibition kinetics were 5, 4, 3, 2, 1, and 0-minutes. All time points used 3 rows
and 12 columns and one plate held two time points except for the 1-minute and 0-minute
time points which were performed separately. Plate 1 held the 5-minute and 3-minute
reactions, plate 2 held the 4-minute and 2-minute reactions, plate 3 held the 1-minute
reaction, and plate 4 held the 0-minute reaction.
The pooled plasma or ghost AChE or BChE was diluted appropriately to ensure
enough sample for all experiments and that the concentration was appropriate to generate
approximately 0.3 absorbance unit. Testing wells were loaded with 250 μl of the
prepared sample with each testing protocol run in triplicate (eserine, ethanol, blank, and
the eight increasing inhibitor concentrations). To the blank wells, DTNB and additional
SPB (0.1M, pH 7.4) was added to obtain FC 0.002 M DTNB in 300 μl total volume.
Eserine sulfate was added to the appropriate control wells to obtain a FC 10-5 M. All
plates were kept on ice until testing. A solution made up of 40% 0.03 M DTNB, 10% 0.1
M ATCh or BTCh, and 50% SPB was mixed and used to initiate the kinetic run and was
kept on ice throughout the experiment to decrease substrate degradation.
A separate plate containing ethanol for the control wells and the various inhibitor
concentrations was set up by adding 150 μl of ethanol to the first four wells and 150 μl of
increasing inhibitor concentrations to the next eight wells. The inhibitory concentrations
ranged from 10% through 90% inhibition and varied depending on the AChE or BChE
source. Tape was placed over the wells and the plate was placed on ice throughout the
testing cycle to decrease evaporation.
Prior to testing a plate, it was warmed and mixed on a Jitterbug plate warmer for
15 minutes at 37 C and at a level 3 shake. While the plate was shaking the
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spectrophotometer plate reader was initiated to run the first plate. Using the multichannel
pipette, 5 μl of the different ethanol and inhibitor solutions was added to the top three
rows of plate one, mixing each time and changing the tips to prevent contamination of the
original ethanol and inhibitory solutions. Once all solutions were added to the top three
rows the timer was started, and a level 3 shake was initiated on the Jitterbug. Solutions
were added to each row utilizing 10 second intervals to maintain uniformity. This is the
initiation of the 5-minute (4-minute) shaking incubation time period.
Thirty seconds prior to the 2-minute mark on the timer, the plate was removed
from the Jitterbug and prepared for the next addition of ethanol and inhibitors. Using the
multichannel pipette, 5 μl of the different solutions was added to the bottom three rows of
wells as performed previously. The plate was quickly returned to the Jitterbug and a
level 3 shake was initiated. Solutions were added to each row utilizing 10 second
intervals to maintain uniformity. This is the 3-minute (2-minute) shaking incubation time
period.
While the plate is shaking in the Jitterbug, an 8-channel repeat pipette was
prepared to dispense 50 μl of the previously prepared DTNB, ATCh (BTCh), and SPB
solution. The incubated and inhibited plate was removed from the shaker and loaded on
the plate reader and the solution was dispensed to all the testing wells, except the blank
wells, and the kinetic read initiated. The 4 and 2-minute plate and 1-minute plate was
performed following the same protocol above.
For the 0-minute assay plate, the plate was warmed and mixed on the Jitterbug for
15 minutes. While the plate was incubating, the plate reader was readied for a kinetic
analysis. After the incubation, the fourth row on the plate was used to contain a mixture
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of 90% DTNB/ATCh(BTCh)/SPB solution and 10% ethanol or inhibitor solutions
(progressing from low to high concentrations). This mixture was added to all the wells
directly below the testing wells except for the blank wells.
The multi-channel pipette was prepared to dispense 50 μl of the solutions in the
fourth well into the three wells above. For each replicate wells above, the solution was
added and thoroughly mixed using the same tip, and the tips were changed before adding
the mixture to the next replicate wells. Once the solutions were added, the plate was
placed on the plate reader and the kinetic program started. Table 15 below depicts the
plate setup for inhibition kinetics. The procedure for rat solid tissue was similar to the
above protocol for blood, but with the same exceptions mentioned in the substrate
kinetics procedure.
Calculations: For each concentration and control, the velocity of each incubation
period was calculated. For each preincubation time, the fraction of AChE or BChE
velocity left ([E]t/[E]0) was calculated by dividing the AChE or BChE velocity following
inhibition ([E]t) by the original uninhibited velocity ([E]0). Using linear regression of the
natural log (ln) of the [E]t/[E]0 as a function of time, should provide a line at each
inhibitor concentration with slope = -kapp. This was the apparent rate of AChE or BChE
phosphorylation. A double reciprocal plot of the kapp as a function of the inhibitor
concentration provided a line with slope = 1/ki, y-intercept = 1/kp, and x-intercept = -KA.
[E] is the concentration of free enzyme.
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Table 15

Plate schematic for inhibition kinetics

Full plate used for 5 and 3-minute time points (rows A, B, C) and 4 and 2-minute time
points (rows F, G, H). Only the top of plate was used for the 1 and 0-minute time points
(rows A, B, C).
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AChE and BChE Reactivation Kinetics Procedure
The volume of specimen required for testing varied depending on the AChE or
BChE sources and the quality of the samples. Initial activity testing was conducted to
determine baseline absorbance for each pool of samples. For testing, the samples were
diluted as necessary to obtain baseline absorbance of approximately 0.3 units.
Preparing the Samples. For ghost AChE specimens: Ghost AChE samples
were pooled and thoroughly homogenized using a glass Tenbroek mortar and pestle and
hemoglobin removed via centrifugation and removal of supernatant at 5000xg for 5
minutes at 4 C (Eppendorf Centrifuge 5415C, F-45-18-11 rotor). The intact sample
pellet was returned to the original volume with SPB (0.1M, pH 7.4) and vortexed.
For plasma: Plasma samples were pooled and not diluted prior to the inhibition
step. Undiluted plasma must be used since the AChE and BChE are suspended in the
plasma. Before the next step, 50 µl of the ghost or plasma sample was pipetted into three
15 ml glass tubes and maintained in the 4oC freezer until protein testing was conducted to
check consistency in specimen preparation.
For solid tissue: Homogenate samples were thawed, pooled and then mixed using
a glass Tenbroek mortar and pestle and then centrifuged at 5000 RCF for 5 minutes at 4
C (Eppendorf Centrifuge 5415C, F-45-18-11 rotor). Once spun down, supernatant was
removed and the pellet left intact. The same volume of fresh Tris buffer (0.05 M, pH 7.4)
was returned to the pelleted specimen and vortexed.
Each experimental parameter and control was carried out in triplicate. The final
volume in each well for blood specimens (ghost and plasma) was 200 μl with 150 μl from
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the diluted enzyme source. The final volume in each well for solid tissue specimens
(brain and skeletal muscle) was 300 μl with 250 μl from the diluted enzyme source. The
final concentration of each solid tissue well was 1 mg equivalent/ml.
Sample Inhibition. For ghosts: The sample was split into two vials, one vial for
the uninhibited sample that was spiked with the ethanol vehicle (minimum 1 ml total
volume) and a second vial for the inhibited sample that was spiked with the appropriate
inhibitor (NIMP or NEMP) which yielded approximately 90% inhibition of the sample
(minimum 5 ml total volume). Incubation was done in a shaking water bath at 37o C at
the necessary time interval to achieve the required 90% inhibition. Once inhibition was
complete the ghosts were centrifuged at 5000xg for 5 minutes at 4C and the supernatant
was removed and the pellet left intact (Eppendorf Centrifuge 5415C, F-45-18-11 rotor).
Removing the supernatant helped to eliminate excess vehicle or surrogate. The pellet
was resuspended to the original volume using SPB and vortexed thoroughly. This wash
procedure was done twice. The last wash was saved for analysis to ensure all the
inhibitor was removed. The washed and inhibited ghost were maintained on ice until
testing. Rat solid tissue followed the same protocol, but Tris buffer was used for the
washes instead of SPB.
For plasma: Since the AChE or BChE is suspended in the plasma, removing the
inhibitor via centrifugation was not possible. To decrease inhibition, the plasma was
diluted. Pre-testing was done to determine the minimal volume of sample and inhibitor
necessary, and the minimal dilution necessary to eliminate further inhibition without
compromising overall enzyme activity and subsequent absorbance. This varied by pool
of plasma, enzyme being tested (AChE or BChE), or species (rat or human).
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Approximately 5 to 15 µl of inhibitor (ethanol for uninhibited control) was used for every
60 µl of plasma. Proportional adjustments were made per pool if more plasma was
needed. Adjustments to the SPB dilution was made per pool as necessary to ensure
optimal enzyme activity for testing. The diluted and inhibited sample was maintained on
ice until testing.
A solution made up of 40% 0.03 M DTNB, 10% 0.1 M ATCh or BTCh, and 50%
SPB (Tris buffer) was mixed and used to initiate the kinetic run and was kept on ice
throughout the experiment to decrease substrate degradation.
Initial Time Point. For the initial time point (0 min), cold uninhibited ghost
(plasma) was vortexed and 68 µl (175 µl for plasma and 100 µl for solid tissue) was
pipetted into a 3 ml glass tube with 2 ml cold buffer. The diluted samples were vortexed
and 250 µl (150 µl solid tissue) pipetted into three rows of a 96-well plate with the rows
representing replicates (A, B, C). Additional columns were loaded as necessary with
column 1 and 2 used for eserine sulfate controls, columns 3 and 4 were ethanol controls.
Rows 2 and 4 were blanks and did not have any ATCh added to them. The same setup
was done for the inhibited samples, but subsequent columns 5 through 8 were set up
accordingly. To the blank wells, DTNB and additional SPB was added to obtain FC
0.002 M DTNB in 200 μl (300 μl for solid tissue) total volume. Eserine sulfate was
added to the appropriate control wells to obtain a FC 10-5 M. The plate was incubated
and mixed in the Jitterbug for 15-minutes at a level 3 mix. While the plate was shaking
the spectrophotometer was set up to run the preset kinetics program. The 8-channel
repeat pipette was prepared to dispense 50 μl of the DTNB/ATCh(BTCh)/SPB solution
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described earlier. Once incubation was done the plate was quickly loaded with the
solution, except for the blank wells, and the plate reader was started.
15, 30, 45, and 60-minute time points. For the reactivation experiment the
inhibited sample was split into 5 aliquots (inhibited sample to monitor spontaneous
reactivation, inhibited sample used to gauge aging, inhibited sample reactivated with 2PAM, inhibited sample reactivated with Oxime 1, and inhibited sample reactivated with
Oxime 2). For each split sample the appropriate ethanol vehicle or oxime was
administered 20 μl for ghost or 50 μl for plasma per 1 ml of sample and vortexed (10
μl/ml for solid tissue). Samples were incubated in a shaking water bath at 37o C and a
timer initiated. The timer was maintained throughout the 60-minute incubation and not
stopped.
At each time point, incubated samples were vortexed and 68 μl for ghost samples
(175 μl for plasma and 100 µl solid tissue) were pipetted into separate glass tubes with 2
ml cold buffer. The aging sample was primed with 30 μl of 2-PAM and incubated in the
37 oC shaking water bath for 10 minutes. The remaining samples were vortexed and 250
µl (150 µl solid tissue) was pipetted into three rows (A, B, C or F, G, H) of a 96-well
plate as appropriate. For the uninhibited sample and inhibited sample with no reactivator
the three rows A, B, and C were utilized as subsamples for each parameter. For each
sample type an eserine control was setup in columns 1 and 2 with the later column used
as the blank, ethanol vehicle controls were setup in columns 3 and 4 with the later
column used as the blank. For inhibited samples the same setup was done using columns
5 through 8.
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For the inhibited samples with reactivators added, rows F, G, and H were used as
subsamples. One column was used for an eserine control and two columns were used to
test the amount of reactivation at the time point (3 columns per reactivator). After setup
was complete, the aging sample was removed from the water bath and setup as well. To
the column with the blank wells, DTNB and additional SPB was added to obtain FC
0.002 M DTNB in 200 μl (300 μl for solid tissue) total volume. Eserine sulfate was
added to the appropriate control wells to obtain a FC 10-5 M.
Once setup was complete the plate was placed in the Jitterbug for a 15-minute
warm-up incubation with a level 3 mix. While the plate was shaking the
spectrophotometer was initiated to run the preset kinetics program. The 8-channel repeat
pipette was prepared to dispense 50 μl of the DTNB/ATCh(BTCh)/SPB solution used
earlier. Once incubation was done the plate was quickly loaded with the solution, except
the blank wells, and the plate reader was started. Table 16 below depicts the plate setup
for reactivation kinetics.
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Table 16
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Plate schematic used for reactivation kinetics

Calculations: Determination of the ratio of AChE (BChE) activity at each time
interval was calculated by dividing the AChE (BChE) activity in the inhibited samples by
the matching control activity ([E]t/[E]0). Using the natural log of the ratio of inhibited
versus control activity (y-axis) at each time point (x-axis), the various rate constants
described below were obtained (kr, ks, ka) with the slope of the best fit line with R2-value
no less than 0.9. All rate constant variables were on the y-axis and the time points were
on the x-axis. First order rate constants were calculated from linear regression of the
natural log (ln) of the ratio of AChE (BChE) activity as a function of time. Using the
vehicle (control) plots, the spontaneous reactivation (s) rate constant, ks, was estimated
from the slope of the line described by the equation ln([E]t/[E]0) = kst. Using the oxime
reactivation plots, the oxime reactivation rate (r) constant, kr, was estimated from the
slope of the line described by the equation ln([E]t/[E]0) = krt. Using the oxime
reactivation plots from the 2-PAM aging data, the aging rate (a) constant, ka, was
estimated from the slope of the line described by the equation ln(1-[E]t/[E]0) = kat. Aging
was determined by incubating a portion of the inhibited sample with a reactivator
(concentration known to reactivate 100% of AChE(BChE)) at set time points and
calculating if any AChE(BChE) was not reactivated. The percent not reactivated was
considered the aged AChE(BChE). The difference between the reactivation and aging
rate constant provided the true reactivation rate constant.
Bio 4 Spectrophotometric Plate Reader Setup
The kinetics program was preset prior to all testing. Measurement mode was set
for absorbance with a measurement wavelength set at 412 nm with a reference
wavelength of 0 nm. The read mode was set at normal with a kinetic cycle of 25 with
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minimum reading time intervals (approximate run time was 8 minutes). The testing
temperature range was set at 35 to 38 C. The plate volume was set at 300 μl for blood
specimens and 200 μl for solid tissue specimens. A shake was set before each
measurement at a 3-second duration, conducted internally, and at normal intensity.
Shaking was conducted between cycles at a 2-second duration, performed internally, and
at normal intensity.
Modified Lowry Protein Determination Procedure
This experiment was utilized to determine the relative protein concentration
within the solid tissue or blood components analyzed and determined the consistency of
the testing solutions. Bovine serum albumin (BSA) was used to set up the standard curve
with concentrations of 0 mg/ml, 50 mg/ml, and 200 mg/ml. All standards and specimens
were analyzed with three individual replicates. The amount of sample needed for blood
assays was 50 μl for each replicate tube. Samples were taken prior to plating and batched
for testing and stored at -20 oC. The standard curve was created by adding 3 ml of
deionized (DI) water to each standard curve tube. Volumes were removed from
respective standards and replaced with BSA. 50 μl and 200 μl of DI water was removed
and replaced with 50 μl and 200 μl of BSA respectively. All tissue and blood samples
received 3 ml of DI water. All tubes were vortexed. Reagent A was made by dissolving
4 g NaOH and 20 g Na2CO3 in 1 L or DI water. Reagent C was created using Reagent A
and NaK tartrate and copper sulfate. The amount of reagent A was calculated based on
number of tubes x 2.5 ml + 50 ml. For every 100 mls of reagent A, 1 ml of NaK tartrate
and 1 ml of copper sulfate was added to reagent C. 2.5 mls of reagent C was added to
every test tube and vortexed. Tubes were left to stand for 10 minutes at room
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temperature. Reagent E was calculated based on the number of tubes x 0.250 mls + 2
mls. Based on this volume the amount of reagent E was created with 50% DI water and
50% Folin reagent. 250 µl of reagent E was added to each test tube and vortexed. Tubes
were left to stand for 30 minutes at room temperature. They were read at 500 nm on a
Thermo Scientific Biomate 3 spectrophotometer. Consistent detection of protein levels
for each type of specimen provided confirmation that analyzed specimens contained
proteins.
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